<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        124-334-09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PRIZMA 4GM-0.5GM POWDER FOR I.V INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PIPERACILLIN,Tazobactam
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4,0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        71.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LABORATORIO REIG JOFRE" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LABORATORIO REIG JOFRE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01CR05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:5.6pt; margin-right:.75pt; text-indent:0in"><!--[if !supportLists]--><!--[endif]-->Piperacillin belongs to the group of medicines known as &ldquo;broad- spectrum penicillin antibiotics&rdquo;. It can kill many kinds of bacteria. Tazobactam can prevent some resistant bacteria from surviving the effects of piperacillin. This means that when piperacillin and tazobactam are given together, more types of bacteria are killed. Prizma is used in adults and adolescents to treat bacterial infections, such as those affecting the lower respiratory tract (lungs), urinary tract (kidneys and bladder), abdomen, skin or blood. Prizma may be used to treat bacterial infections in patients with low white blood cell counts (reduced resistance to infections).</p><p style="margin-left:5.6pt; margin-right:4.95pt">Prizma is used in children aged 2-12 years to treat infections of the abdomen such as appendicitis, peritonitis (infection of the fluid and lining of the abdominal organs), and gallbladder (biliary) infections. Prizma may be used to treat bacterial infections in patients with low white blood cell counts (reduced resistance to infections).</p><p style="margin-left:5.6pt; margin-right:-.35pt">In certain serious infections, your doctor may consider using Prizma in combination with other antibiotics.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Prizma</strong></p><ul><li>&nbsp;If you are allergic to piperacillin or tazobactam or any of the other ingredients of this medicine (listed in section 6).</li><li>If you are allergic to antibiotics known as penicillins, cephalosporins or other beta-lactamase inhibitors, as you may be allergic to Prizma.</li></ul><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before using Prizma:</p><ul><li>If you have allergies. If you have several allergies, make sure you tell your doctor or other healthcare professional before receiving this product.</li><li>If you are suffering from diarrhoea before, or if you develop diarrhoea during or after your treatment. In this case, make sure you tell your doctor or other healthcare professional immediately. Do not take any medicine for the diarrhoea without first checking with your doctor.</li><li>If you have low levels of potassium in your blood. Your doctor may want to check your kidneys before you take this medicine and may perform regular blood tests during treatment.</li><li>If you have kidney or liver problems, or are receiving haemodialysis. Your doctor may want to check your kidneys before you take this medicine, and may perform regular blood tests during treatment.</li><li>If you are taking certain medicines (called anticoagulants) to avoid an excess of blood clotting (see also &ldquo;Other medicines and Prizma&rdquo; in this leaflet) or any unexpected bleeding occurs during the treatment. In this case, you should inform your doctor or other healthcare professional immediately.</li><li>If you develop convulsions during the treatment. In this case, you should inform your doctor or other healthcare professional.</li><li>If you think you developed a new or worsening infection. In this case, you should inform your doctor or other healthcare professional.</li></ul><p><strong>Children</strong></p><p>Piperacillin/tazobactam is not recommended for use in children below the age of 2 years due to insufficient data on safety and effectiveness.</p><p><strong>Other medicines and Prizma </strong></p><p>Tell your doctor or other healthcare professional if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription. Some medicines may interact with piperacillin and tazobactam.</p><p>These include:</p><ul><li>Medicine for gout (probenecid). This can increase the time it takes for piperacillin and tazobactam to leave your body.</li><li>Medicines to thin your blood or to treat blood clots (e.g. heparin, warfarin or aspirin).</li><li>Medicines used to relax your muscles during surgery. Tell your doctor if you are going to have a general anaesthetic.</li><li>Methotrexate (medicine used to treat cancer, arthritis or psoriasis). Piperacillin and tazobactam can increase the time it takes for methotrexate to leave your body.</li><li>&nbsp;Medicines that reduce the level of potassium in your blood (e.g. tablets enhancing urination or some medicines for cancer).</li><li>Medicines containing the other antibiotics tobramycin, gentamicin or vancomycin. Tell your doctor if you have kidney problems.</li></ul><p><strong>Effect on laboratory tests </strong></p><p>Tell the doctor or laboratory staff that you are taking Prizma if you have to provide a blood or urine sample.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or other healthcare professional for advice before receiving this medicine. Your doctor will decide if Prizma is right for you.</p><p>Piperacillin and tazobactam can pass to a baby in the womb or through breast milk. If you are breast-feeding, your doctor will decide if Prizma is right for you.</p><p><strong>Driving and using machines</strong></p><p>The use of piperacillin/tazobactam is not expected to affect the ability to drive or use machines.</p><p><strong>Prizma contains sodium</strong></p><p>Prizma contains sodium. Each vial of 2 g/0.25 g and 4 g/0.5 g contains 108.1 mg or 216.1 mg sodium; respectively. This should be taken into consideration if you are on a controlled-sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor or other healthcare professional will give you this medicine through an infusion (a drip for 30 minutes) into one of your veins.</p><p><strong>Dosage</strong></p><p>The dose of medicine given to you depends on what you are being treated for, your age, and whether or not you have kidney problems.</p><p><strong>Adults and adolescents above 12 years of age</strong></p><p>The usual dose is 4 g/0.5 g of piperacillin/tazobactam given every 6-8 hours, which is given into one of your veins (directly into the blood stream).</p><p><strong>Children aged 2 to 12 years</strong></p><p>The usual dose for children with abdominal infections is 100 mg/12.5 mg/kg of body weight of piperacillin/tazobactam given every 8 hours into one of your veins (directly into the blood stream). The usual dose for children with low white blood cell counts is 80 mg/10 mg/kg of body weight of piperacillin/tazobactam given every 6 hours into one of your veins (directly into the blood stream).</p><p>Your doctor will calculate the dose depending on your child&rsquo;s weight but each individual dose will not exceed 4 g/0.5 g of Prizma.</p><p>You will be given Prizma until the sign of infection has gone completely (5 to 14 days).</p><p><strong>Patients with kidney problems </strong></p><p>Your doctor may need to reduce the dose of Prizma or how often you are given it. Your doctor may also want to test your blood to make sure that your treatment is at the right dose, especially if you have to take this medicine for a long time.</p><p><strong>If you receive more Prizma than you should</strong></p><p>As you will receive Prizma from a doctor or other healthcare professional, you are unlikely to be given the wrong dose. However, if you experience side effects, such as convulsions, or think you have been given too much, tell your doctor immediately.</p><p><strong>If you miss a dose of Prizma</strong></p><p>If you think you have not been given a dose of Prizma, tell your doctor or other healthcare professional immediately</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>See a doctor immediately if you experience any of these potentially serious side effects of piperacillin/tazobactam:</p><p>The serious side effects (with frequency in brackets) of piperacillin/ tazobactam are:</p><ul><li>&nbsp;Serious skin rashes [Stevens-Johnson syndrome, dermatitis bullous (Not known), dermatitis exfoliative (Not known), toxic epidermal necrolysis (Rare)] appearing initially as reddish target-like spots or circular patches often with central blisters on the trunk. Additional signs include ulcers in the mouth, throat, nose, extremities, genitals and conjunctivitis (red and swollen eyes). The rash may progress to widespread blistering or peeling of the skin and potentially may be life-threatening</li><li>Severe potentially fatal allergic condition (drug reaction with eosinophilia and systemic symptoms) that can involve the skin and most importantly other organs under the skin such as the kidney and the liver</li><li>A skin condition (acute generalised exanthematous pustulosis) accompanied by fever, which consists of numerous tiny fluid filled blisters contained within large areas of swollen and reddened skin</li><li>Swelling of the face, lips, tongue or other parts of the body (Not known)</li><li>Shortness of breath, wheezing or trouble breathing (Not known)</li><li>Severe rash or hives (Uncommon), itching or rash on the skin (Common)</li><li>Yellowing of the eyes or skin (Not known)</li><li>Damage to blood cells [the signs include: being breathless when you do not expect it, red or brown urine (Not known), nosebleeds (Rare) and small spot bruising (Not known)], severe decrease in white blood cells (Rare)</li><li>Severe or persistent diarrhoea accompanied by a fever or weakness (Rare).</li></ul><p>If any of the following side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or other healthcare professional.</p><p><strong>Very common side effects </strong>(may affect more than 1 in 10 people):</p><ul><li>Diarrhoea</li></ul><p><strong>Common side effects</strong> (may affect up to 1 in 10 people):</p><ul><li>&nbsp;Yeast infection</li><li>Decrease in platelets, decrease of red blood cells or blood pigment/ haemoglobin, abnormal lab test (positive direct Coombs), prolonged blood clotting time (activated partial thromboplastin time prolonged)</li><li>Decrease in blood protein</li><li>Headache, sleeplessness</li><li>Abdominal pain, vomiting, nausea, constipation, upset stomach</li><li>Increase in blood liver enzymes</li><li>Skin rash, itching</li><li>Abnormal kidney blood tests</li><li>Fever, injection site reaction</li></ul><p><strong>Uncommon side effects</strong> (may affect up to 1 in 100 people):</p><ul><li>Decrease in white blood cells (leukopenia), prolonged blood clotting time (prothrombin time prolonged)</li><li>Decreased blood potassium, decreased blood sugar</li><li>Fits (convulsions), seen in patients on high doses or with kidney problems</li><li>Low blood pressure, inflammation of the veins (felt as tenderness or redness in the affected area), reddening of skin</li><li>Increase of a blood pigment breakdown product (bilirubin)</li><li>Skin reactions with redness, formation of skin lesions, nettle rash</li><li>Joint and muscle pain</li><li>Chills</li></ul><p><strong>Rare side effects</strong> (may affect up to 1 in 1,000 people):</p><ul><li>Severe decrease in white blood cells (agranulocytosis), bleeding of the nose</li><li>Serious infection of the colon, inflammation of the mucous lining of the mouth</li><li>Detachment of the top layer of the skin all over the body (toxic epidermal necrolysis)</li></ul><p><strong>Not known</strong> (cannot be estimated from the available data) <strong>side effects</strong>:</p><ul><li>Severe decrease of red blood cells, white blood cells and platelets (pancytopenia), decrease in white blood cells (neutropenia), decrease of red blood cells due to premature breakdown or degradation, small spot bruising, bleeding time prolonged, increase of platelets, increase of a specific type of white blood cells (eosinophilia)</li><li>Allergic reaction and severe allergic reaction</li><li>&nbsp; Inflammation of the liver, yellow staining of the skin or whites of the eyes</li><li>Serious body wide allergic reaction with skin and mucous lining rashes, blistering and various skin eruptions (Stevens-Johnson Syndrome), severe allergic condition involving skin and other organs such as the kidney and the liver (drug reaction with eosinophilia and systemic symptoms), numerous tiny fluid filled blisters contained within large areas of swollen and reddened skin accompanied by fever (acute generalised exanthematous pustulosis), skin reactions with blistering (dermatitis bullous)</li><li>Poor kidney functions and kidney problems</li><li>A form of lung disease where eosinophils (a form of white blood cell) appear in the lung in increased numbers</li><li>Acute disorientation and confusion (delirium)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Beta-lactam antibiotics, including piperacillin tazobactam, may lead to signs of altered brain function (encephalopathy) and convulsions.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Unopened vial: Do not store above 30&deg;C.</p><p>Store in the original package.</p><p>For single use only. Discard any unused solution.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use.</p><p>These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are piperacillin sodium and tazobactam sodium.</p><p>Each vial of Prizma 2 g/0.25 g Powder for Solution for Infusion contains 2.085 g piperacillin sodium equivalent to 2 g piperacillin and 0.2683 g tazobactam sodium equivalent to 0.25 g tazobactam.</p><p>Each vial of Prizma 4 g/0.5 g Powder for Solution for Infusion contains 4.17 g piperacillin sodium equivalent to 4 g piperacillin and 0.5366 g tazobactam sodium equivalent to 0.5 g tazobactam.</p><p>There are no other ingredients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Prizma 2 g/0.25 g and 4 g/0.5 g Powder for Solution for Infusion is white or almost white sterile loose lump or powder in type II glass transparent 
vials with a bromobutyl stoppers and aluminum flip-off caps.
Pack size: 1 Vial.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Batch releaser</strong></p><p>Jazeera Pharmaceutical Industries</p><p>Al-Kharj Road</p><p>P.O. BOX 106229</p><p>Riyadh 11666, Saudi Arabia</p><p>Tel: + (966-11) 8107023, + (966-11) 2142472</p><p>Fax: + (966-11) 2078170</p><p>e-mail: SAPV@hikma.com</p><p>B<strong>ulk manufacturer and Under licensed from</strong></p><p>Laboratory Reig Jofre S.A.</p><p>C/Jarama 111 Pol&iacute;gono Industrial</p><p>45007, Toledo</p><p>Spain</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 05/2021; version number Un2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي بيبيراسيلين إلى مجموعة الأدوية المعروفة باسم &rdquo;المضادات الحيوية البينيسيلينية واسعة الزمرة&ldquo;. وهي قادرة على القضاء على العديد من أنواع البكتيريا.</p><p>يستطيع أن يمنع تازوباكتام بعض البكتيريا المقاومة لاثار البيبيراسيلين من البقاء على قيد الحياة. ويعني ذلك أنه عندما يتم إعطاء بيبيراسيلين وتازوباكتام معا فإنه يتم القضاء على أنواع أكثر من البكتيريا.</p><p>يستخدم بريزما لدى البالغين والمراهقين لعلاج العدوى البكتيرية، مثل العدوى التي تصيب الجهاز التنفسي السفلي (الرئتين)، الجهاز البولي (الكلى والمثانة)، البطن، الجلد أو الدم.</p><p>قد يستخدم بريزما لعلاج العدوى البكتيرية لدى المرضى الذين يعانون من انخفاض عدد كريات الدم البيضاء (انخفاض المقاومة للعدوى).</p><p>يستخدم بريزما لدى الأطفال الذين تتراوح أعمارهم بين عامين و12 عامالعلاج عدوى البطن مثل التهاب الزائدة، والتهاب الصفاق(عدوى السوائل وبطانة أعضاء البطن)، وعدوى المرارة (الصفراوية). قد يستخدم بريزما لعالج العدوى البكتيرية لدى المرضى الذين يعانون من انخفاض عدد كريات الدم البيضاء (انخفاض المقاومة للعدوى).</p><p>قد يرى الطبيب ضرورة استخدام بريزما مع مضادات حيوية أخرى في حالات خطيرة محددة من العدوى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستخدم بريزما</strong></p><ul><li dir="rtl"><strong>&nbsp;</strong>إذا كنت تعاني من حساسية لبيبيراسيلين أو تازوباكتام أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6) .</li><li dir="rtl">إذا كنت تعاني من حساسية للمضادات الحيوية المعروفة بالبينيسيلينات، السيفالوسبورينات أو مثبطات البيتا-لاكتاماز الأخرى، فقد تعاني من حساسية تجاه بريزما.</li></ul><p><strong>الاحتياطات والتحذيرات</strong></p><p>تحدث مع طبيبك، الصيدلي أو الممرض قبل استخدام بريزما:</p><ul><li dir="rtl">إذا كنت تعاني من حساسية. إذا كنت تعاني من العديد من الحساسية، تأكد من التحدث إلى طبيبك أو إلى شخص آخر من متخصصي الرعاية الصحية قبل استخدام هذا المستحضر.</li><li dir="rtl">إذا كنت تعاني من الإسهال قبل استخدام الدواء، أو إذا أصبت بالإسهال أثناء أو بعد استخدامه. في هذه الحالة، احرص على التحدث إلى طبيبك أو إلى شخص آخر من متخصصي الرعاية الصحية على الفور. لا تتناول أي دواء لعلاج&nbsp;الإسهال دون التحقق أولا من طبيبك.</li><li dir="rtl">إذا كنت تعاني من انخفاض مستويات البوتاسيوم في الدم. قد يطلب طبيبك فحص الكلى قبل تناول هذا الدواء وقد يُجري فحوصات للدم بشكل منتظم أثناء العلاج.</li><li dir="rtl">إذا كنت تعاني من مشاكل بالكلى أو بالكبد، أو إذا كنت تخضع لغسيل الكلى. قد يطلب طبيبك فحص الكلى قبل تناول هذا الدواء وقد يُجري فحوصات للدم بشكل منتظم أثناء العلاج.</li><li dir="rtl">إذا كنت تتناول أدوية معينة (يُطلق عليها مضادات التخثر) وذلك لتجنب زيادة تجلط الدم (انظر أيضا &rdquo;الأدوية الأخرى وبريزما&ldquo; في هذه النشرة) أو إذا حدث أي نزيف غير متوقع أثناء العلاج. في هذه الحالة، ينبغي عليك إخبار طبيبك أو أي شخص آخر من متخصصي الرعاية الصحية على الفور.</li><li dir="rtl">إذا أصبت باختلاجات أثناء العلاج. في هذه الحالة، ينبغي عليك إخبار طبيبك أو أي شخص آخر من متخصصي الرعاية الصحية</li><li dir="rtl">إذا كنت تعتقد أن العدوى تزداد سوءا أو أنك صبت بعدوى جديدة. في هذه الحالة، ينبغي عليك إخبار طبيبك أو أي شخص آخر من متخصصي الرعاية الصحية.</li></ul><p><strong>الأطفال</strong></p><p>لايوصى باستخدام بيبيراسيلين/تازوباكتام لدى الأطفال الذين تقل أعمارهم عن عامين وذلك لعدم وجود البيانات الكافية حول سلامة وفاعلية هذا الدواء لديهم.</p><p><strong>الأدوية الأخرى وبريزما</strong></p><p>أخبر طبيبك أو أي شخص آخر من متخصصي الرعاية الصحية إذا كنت تأخذ أو أخذت مؤخرا أو قد تأخذ أية أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p>قد تتداخل بعض الأدوية مع بيبيراسيلين وتازوباكتام.</p><p>وتشمل:</p><ul><li dir="rtl">دواء لعلاج النقرس (بروبينيسيد). يمكن أن يزيد هذا الدواء من المدة التي يستغرقها بيبيراسيلين وتازوباكتام للخروج من الجسم.</li><li dir="rtl">أدوية لزيادة سيولة الدم أو لعلاج الجلطات الدموية (مثل الهيبارين، الوارافارين أو الأسبرين).</li><li dir="rtl">الأدوية التي تستخدم لإرخاء العضلات أثناء الجراحة. أخبر طبيبك إذا كنت ستخضع لتخدير عام.</li><li dir="rtl">ميثوتريكسات (دواء يستخدم لعلاج&nbsp;&nbsp;السرطان، التهاب المفاصل أو الصدفية). يمكن أن يزيد دواء بيبيراسيلين وتازوباكتام من المدة التي يستغرقها ميثوتريكسات للخروج من الجسم.</li><li dir="rtl">الأدوية التي تعمل على تقليل مستوى البوتاسيوم في الدم (مثل الأقراص التي تحسن التبول أو بعض أدوية السرطان).&nbsp;</li><li dir="rtl">الأدوية التي تحتوي على المضادات الحيوية الأخرى مثل توبراميسين، جنتاميسين أو ڤانكوميسين. أخبر طبيبك إذا كنت تعاني من مشاكل بالكلى.</li></ul><p><strong>التأثير على فحوصات المختبر</strong></p><p>أخبر الطبيب أو طاقم المختبر بأنك تستخدم بريزما إذا كان يتعين عليك تقديم عينة دم أو بول.</p><p><strong>الحمل والرضاعة</strong></p><p>يرجى استشارة طبيبك أو متخصص الرعاية الصحية قبل تلقي هذا الدواء، إذا كنت حاملا أو تقومين بالرضاعة، تعتقدين بأنك حامل أو تخططين لذلك. وسوف يحدد طبيبك ما إذا كان بريزما يناسبك أم لا.</p><p>قد ينتقل بيبيراسيلين وتازوباكتام إلى الطفل في الرحم أو من خلال حليب الثدي. إذا كنت ترضعين رضاعة طبيعية، فسوف يحدد طبيبك ما إذا كان بريزما يناسبك أم لا.</p><p><strong>القيادة واستخدام الالات</strong></p><p>ليس من المتوقع أن يؤثر استخدام بيبيراسيلين/تازوباكتام على القدرة على القيادة أو استخدام الالات.</p><p><strong>يحتوي بريزما على الصوديوم</strong></p><p>يحتوي بريزما على الصوديوم. تحتوي كل زجاجة من 2 غم/0.25 غم و4 غم/0.5غم على 108.1 ملغم أو 216.1 ملغم صوديوم؛ على التوالي. ينبغي وضع ذلك في عين الإعتبار إذا كنت تتبع نظاما غذائيا يتم فيه التحكم في كمية الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سوف يعطيك طبيبك أو متخصص الرعاية الصحية هذا الدواء من خلال التسريب (تنقيط لمدة 30 دقيقة) في أحد الأوردة.</p><p><strong>الجرعة</strong></p><p>تعتمد جرعة الدواء المعطاة على نوع العدوى التي يتم علاجها والعمر وما إذا كنت تعاني من مشاكل في الكلى.</p><p><strong>البالغون والمراهقون الذين تبلغ أعمارهم أكثر من 12 عاما</strong></p><p>&nbsp;الجرعة المعتادة هي 4 غم/0.5 غم من بيبيراسيلين/تازوباكتام تعطى كل 6 إلى 8 ساعات في أحد الأوردة (في مجرى الدم مباشرة).</p><p><strong>الأطفال الذين تتراوح أعمارهم من عامين إلى 12 عاما</strong></p><p>الجرعة المعتادة للأطفال الذين يعانون من عدوى بطنية هي100 ملغم/12.5 ملغم/كغم من وزن الجسم من بيبيراسيلين/تازوباكتام وتعطى كل 8 ساعات في أحد الأوردة (في مجرى الدم مباشرة). الجرعة المعتادة للأ طفال الذين يعانون من انخفاض عدد كريات الدم البيضاء هي 80ملغم/10 ملغم/كغم من وزن الجسم من بيبيراسيلين/تازوباكتام وتعطى كل 6 ساعات في أحد الأوردة (في مجرى الدم مباشرة).</p><p>سوف يحسب الطبيب الجرعة حسب وزن طفلك، إلا أن كل جرعة فردية لن تتجاوز 4 غم/0.5 غم من بريزما.</p><p>سيتم إعطاؤك بريزما إلى أن تختفي علامات العدوى تماما(من 5 إلى 14 يوم).</p><p><strong>المرضى الذين يعانون من مشاكل في الكلى</strong></p><p>قد يحتاج طبيبك إلى تقليل جرعة بريزما أو عدد المرات التي يتم إعطاؤك فيها هذه الجرعة. قد يرغب طبيبك أيضا في إجراء اختبار دم للتأكد من أنه يتم علاجك بالجرعة المناسبة، لا سيما إذا كان عليك استخدام هذا الدواء لفترة طويلة.</p><p><strong>إذا تلقيت بريزما أكثر من اللازم</strong></p><p>نظرا لأنك ستتلقى بريزما بمعرفة طبيب أو متخصص رعاية صحية آخر، فمن غير المحتمل أن يتم إعطاؤك الجرعة الخطأ. ومع ذلك، إذا كنت تعاني من آثار جانبية، مثل الاختلاجات، أو كنت تعتقد أنك قد تناولت جرعة زائدة، فأخبر طبيبك على الفور.</p><p><strong>إذا نسيت تناول جرعة من بريزما</strong></p><p>إذا كنت تعتقد أنه لم يتم إعطاؤك جرعة من بريزما، فأخبر طبيبك أو أي شخص آخر من متخصصي الرعاية الصحية على الفور.</p><p>إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، يرجى استشارة طبيب أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع االأدوية، قد يسبب هذا الدواء آثارا&nbsp; جانبية،&nbsp; إلا أنه ليس بالضرورة تحدث لدى جميع مستخدمي هذا الدواء.</p><p>يجب استشارة الطبيب على الفور إذا أصبت بأي من آثار بيبيراسيلين/تازوباكتام الجانبية الخطيرة التالية:</p><p>الاثار الجانبية الخطيرة (ومع درجة تكرارها بين الأقواس) لبيبيراسيلين/تازوباكتام هي:</p><ul><li dir="rtl">حالات خطيرة من الطفح الجلدي [متلازمة ستيفنز جونسون، التهاب الجلد الفقاعي (غير معروفة)، التهاب الجلد التقشري (غير معروفة)، تقشر الأنسجة المتموتة البشروية التسممي (نادرة) ] والتي تظهر في البداية على هيئة نقاط أو بقع دائرية حمراء على الجذع تظهر غالبا في وسطها نقطات. تشمل العلامات الإضافية تقرحات في الفم، الحلق، الأنف،الأطراف، الأعضاء التناسلية والتهاب الملتحمة (احمرار وتورم العينين). قد يتحول الطفح الجلدي إلى بثور منتشرة أو تقشر في الجلد وقد يكون مهدد للحياة أحيانا</li><li dir="rtl">حالة تحسسية شديدة قد تكون مميتة (تفاعل دوائي يصاحبه أعراض جهازية وكثرة اليوزينيات) والتي يمكن أن تصيب الجلد والأهم من ذلك الأعضاء الأخرى تحت الجلد مثل الكلى والكبد</li><li dir="rtl">حالة جلدية (داء البثور الطفحية المعمم الحاد) تصاحبها حمى، وتتكون من نفطات صغيرة عديدة ممتلئة بالسوائل في مناطق جلدية حمراء متورمة في مناطق واسعة من الجسم</li><li dir="rtl">تورم الوجه، الشفتين، اللسان أو أي أجزاء أخرى من الجسم (غير معروفة)</li><li dir="rtl">ضيق التنفس، صفير أو صعوبة في التنفس (غير معروفة)</li><li dir="rtl">طفح جلدي شديد أو شرى (غير شائعة)، أو حكة أو طفح على الجلد (شائعة)</li><li dir="rtl">اصفرار العينين أو الجلد (غير معروفة)</li><li dir="rtl">تلف خلايا الدم [ وتشمل العلامات: الشعور بضيق التنفس عند عدم توقع ذلك، بول أحمر أو بني (غير معروفة)، نزف الأنف (نادرة) وكدمات على شكل بقع صغيرة (غير معروفة) ] ، انخفاض شديد في خلايا&nbsp;الدم البيضاء (نادرة)</li><li dir="rtl">إسهال شديد أو مستمر مصحوب بحمى أو ضعف (نادرة).</li></ul><p>يرجى الاتصال بطبيبك أو متخصص الرعاية الصحية في حال أصبحت أي من الاثار الجانبية أكثر سوءا ً أو في حال ظهور أي آثار جانبية جديدة لم تذكر في هذه النشرة.</p><p><strong>آثار جانبية شائعة جدا</strong> (قد تؤثر على أكثر من 1 من كل 10 أشخاص)</p><ul><li>إسهال&nbsp;</li></ul><p><strong>آثار جانبية شائعة </strong>(قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص):</p><ul><li dir="rtl">عدوى فطرية</li><li dir="rtl">&nbsp;انخفاض في الصفائح، انخفاض في خلايا الدم الحمراء أو صباغ الدم/الهيموغلوبين، نتائج غير طبيعية في فحوصات المختبر (نتيجة إيجابية باختبار كومبس المباشر)، إطالة زمن تجلط الدم (إطالة زمن الثرومبوبلاستين&nbsp;الجزئي المنشط)</li><li dir="rtl">انخفاض في بروتين الدم</li><li dir="rtl">صداع، أرق</li><li dir="rtl">&nbsp;ألم في البطن، قيء، غثيان، إمساك، اضطراب في المعدة</li><li dir="rtl">زيادة في إنزيمات الكبد في الدم</li><li dir="rtl">&nbsp;طفح جلدي، حكة</li><li dir="rtl">نتائج غير طبيعية لاختبارات فحص وظائف الكلى التي تظهر في فحوصات الدم</li><li dir="rtl">&nbsp; حمى، تفاعل عند موضع الحقن</li></ul><p><strong>آثار جانبية غير شائعة</strong> (قد تؤثر على ما يصل إلى 1 من كل 100 شخص):</p><ul><li dir="rtl">انخفاض في خلايا الدم البيضاء (قلة الكريات البيض)، إطالة زمن تجلط الدم (إطالة زمن البروثرومبين)</li><li dir="rtl">انخفاض البوتاسيوم في الدم، انخفاض السكر في الدم</li><li dir="rtl">&nbsp;اختلاجات (تشنجات)، تم ملاحظتها في المرضى مع الجرعات العالية أو مع مشاكل الكلى</li><li dir="rtl">&nbsp;انخفاض ضغط الدم، التهاب الأوردة (الشعور بألم أو احمرار بالمنطقة المصابة)، احمرار الجلد</li><li dir="rtl">زيادة ناتج تحلل الصباغ الدموي (البيليروبين)</li><li dir="rtl">ردود فعل جلدية مصحوبة باحمرار، تكون آفات بالجلد، مرض الشرى الطفحي القراصي</li><li dir="rtl">&nbsp;ألم في المفاصل والعضلات</li><li dir="rtl">قشعريرة</li></ul><p><strong>آثار جانبية نادرة</strong> (قد تؤثر على ما يصل إلى 1 من كل 1,000 شخص):</p><ul><li dir="rtl">انخفاض شديد في خاليا الدم البيضاء (ندرة المحببات)، نزف الأنف</li><li dir="rtl">عدوى خطيرة بالقولون، التهاب بطانة الفم المخاطية</li><li dir="rtl">انفصال الطبقة العلوية للجلد في الجسم بأكمله (تقشر الأنسجة المتموتة البشروية التسممي)</li></ul><p><strong>آثار جانبية غير معروفة </strong>(لا يمكن تقدير شيوعها من البيانات المتاحة):</p><ul><li dir="rtl">انخفاض شديد في خلايا&nbsp;الدم الحمراء، وخلايا&nbsp;الدم البيضاء والصفائح (قلة الكريات الشاملة)، انخفاض في خلايا&nbsp;الدم البيضاء (قلة العدلات)، انخفاض في خلايا الدم الحمراء نظرا للتكسر أو التحلل المبكر، كدمات على شكل بقع صغيرة، إطالة في زمن النزيف، زيادة الصفائح، زيادة نوع معين من خلايا الدم البيضاء (كثرة اليوزينيات)</li><li dir="rtl">رد فعل تحسسي ورد فعل تحسسي شديد</li><li dir="rtl">&nbsp;التهاب الكبد، اصفرار الجلد أو اصفرار بياض العينين</li><li dir="rtl">رد فعل تحسسي خطير ومنتشر على الجسم يصاحبه طفح بالأغشية المخاطية والجلد، ونفطات وطفح جلدي متنوع الأشكال(متلازمة ستيفنز جونسون)، حالة تحسسية شديدة تتضمن الجلد وأعضاء أخرى مثل الكلى والكبد (تفاعل دوائي يصاحبه أعراض جهازية وكثرة اليوزينيات)، ونفطات صغيرة عديدة ممتلئة بالسوائل في مناطق جلدية حمراء متورمة في مناطق واسعة من الجسم مصحوبة بحمى(داء البثور الطفحية المعمم الحاد)، تفاعلات جلدية مع نفطات (التهاب الجلد الفقاعي)</li><li dir="rtl">ضعف في وظائف الكلى ومشاكل بالكلى</li><li dir="rtl">&nbsp;أحد أشكال الأمراض الرئوية حيث تظهر اليوزينيات (نوع من خلايا الدم البيضاء) في الرئة بأعداد متزايدة.</li><li dir="rtl">&nbsp; توهان حاد وارتباك (هذيان)</li></ul><p>ارتبط العلاج باستخدام بيبيراسيلين بحدوث متزايد للحمى والطفح الجلدي لدى مرضى التليف الكيسي.</p><p>قد تؤدي المضادات الحيوية من مجموعة بيتا-لاكتام، بما في ذلك بيبيراسيلين تازوباكتام، إلى ظهور علامات على وظائف المخ المتغيرة (اعتلال الدماغ) وتشنجات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p>الزجاجة غير المفتوحة: لا يحفظ عند درجة حرارة أعلى من 30 &deg;مئوية.</p><p>يحفظ داخل العبوة الأصلية.</p><p>للاستخدام لمرة واحدة فقط. تخلص من أي محلول غير مستخدم.</p><p>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصالحية المذكور على العبوة الخارجية بعد &rdquo;EXP .&rdquo;يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p>لا تستخدم هذا الدواء إذا لاحظت علامات تلف واضحة عليه.</p><p>لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية ,اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المواد الفعالة هي بيبيراسيلين الصوديوم وتازوباكتام الصوديوم.</p><p>تحتوي كل زجاجة من بريزما 2 غم/0.25غم مسحوق للحل للتسريب على2.085 غم بيبيراسيلين الصوديوم يكافئ 2 غم بيبيراسيلين و0.2683 غم تازوباكتام الصوديوم يكافئ 0.25 غم تازوباكتام.</p><p>تحتوي كل زجاجة من بريزما 4 غم/0.5 غم مسحوق للحل للتسريب على 4.17 غم بيبيراسيلين الصوديوم يكافئ 4 غم بيبيراسيلين و0.5366 غم تازوباكتام الصوديوم يكافئ 0.5 غم تازوباكتام.</p><p>لا يوجد مكونات أخرى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>بريزما 2 غم/0.25 غم و4 غم/0.5 غم مسحوق للحل للتسريب هو مسحوق لونه أبيض أو مائل إلى الأبيض يأتي على شكل كتلة مفتتة معقمة في زجاجات شفافة من النوع رقم ٢ مع سدادات من مادة البروموبيوتيل وأغطية من الألومنيوم قابلة للفتح للأعلى</p><p>حجم العبوة: زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>اسم وعنوان مالك رخصة التسويق</strong> <strong>ومحرر التشغيلة</strong></p><p>شركة الجزيرة للصناعات الدوائية</p><p>طريق الخرج</p><p>صندوق بريد106229</p><p>الرياض 11666 ،المملكة العربية السعودية</p><p style="text-align:right">هاتف: 8107023(11_966)+&nbsp;,2142472(11-9966)+</p><p style="text-align:right">فاكس: 2078170(11-966)+&nbsp;&nbsp;&nbsp;</p><p>البريد&nbsp; الالكتروني: SAPV@hikma.com</p><p><strong>الشركة المصنعة للمستحضر النهائي وبترخيص من</strong></p><p>شركة مختبر ريج جوفري العامة المحدودة</p><p>سي/جاراما 111 المنطقة الصناعية</p><p>45007 ،توليدو</p><p>أسبانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ ٠٥/٢٠٢١؛ رقم النسخة 0.Un2
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prizma 4 g/0.5 g Powder for Solution for Infusion 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each  vial  contains  4.17  g  piperacillin  sodium  equivalent  to  4g  piperacillin  and  0.5366g tazobactam sodium equivalent to 0.5 g tazobactam. 
Excipient with known effect: Sodium. 
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion.   
White or almost white sterile loose lump or powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prizma&nbsp;is&nbsp;indicated&nbsp; for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; the&nbsp; following&nbsp; infections&nbsp; in&nbsp;adults&nbsp;and&nbsp; children&nbsp; over&nbsp; 2&nbsp; years&nbsp;of&nbsp;age&nbsp;(see&nbsp;sections&nbsp;4.2&nbsp;and&nbsp;5.1):&nbsp;</p><p><u>Adults&nbsp;and&nbsp;adolescents</u>&nbsp;&nbsp;</p><ul><li>&nbsp;Severe&nbsp;pneumonia&nbsp;including&nbsp;hospital‐acquired&nbsp;and&nbsp;ventilator‐associated&nbsp;pneumonia</li><li>&nbsp; Complicated&nbsp;urinary&nbsp;tract&nbsp;infections&nbsp;(including&nbsp;pyelonephritis)</li><li>&nbsp;Complicated&nbsp;intra‐abdominal&nbsp;infections</li><li>&nbsp; Complicated&nbsp;skin&nbsp;and&nbsp;soft&nbsp;tissue&nbsp;infections&nbsp;(including&nbsp;diabetic&nbsp;foot&nbsp;infections)&nbsp;</li></ul><p>Treatment&nbsp; of&nbsp; patients&nbsp;with&nbsp; bacteraemia&nbsp; that&nbsp; occurs&nbsp; in&nbsp;association&nbsp;with,&nbsp; or&nbsp;is&nbsp; suspected&nbsp; to&nbsp; be &nbsp; associated&nbsp;with,&nbsp;any&nbsp;of&nbsp;the&nbsp;infections&nbsp;listed&nbsp;above.&nbsp; Prizma&nbsp;may&nbsp;be&nbsp;used&nbsp;in&nbsp;the&nbsp;management&nbsp;of&nbsp;neutropenic&nbsp;patients&nbsp;with&nbsp;fever&nbsp;suspected&nbsp;to&nbsp;be&nbsp;due&nbsp; to&nbsp;a&nbsp;bacterial&nbsp;infection.&nbsp;&nbsp;</p><p>Note:&nbsp; Use&nbsp; for&nbsp; bacteraemia&nbsp; due&nbsp; to&nbsp; extended‐beta‐lactamase&nbsp; (ESBL)&nbsp; producing&nbsp;E.&nbsp; coli&nbsp;and&nbsp;K.&nbsp; pneumoniae&nbsp;(ceftriaxone&nbsp; non‐susceptible),&nbsp; is&nbsp; not&nbsp; recommended&nbsp; in&nbsp; adult&nbsp; patients,&nbsp; see&nbsp; section&nbsp; 5.1.&nbsp;</p><p><u>Children&nbsp;2&nbsp;to&nbsp;12&nbsp;years&nbsp;of&nbsp;age</u>&nbsp;</p><ul><li>Complicated&nbsp;intra‐abdominal&nbsp;infections&nbsp;&nbsp;</li></ul><p>Prizma&nbsp;may&nbsp;be&nbsp;used&nbsp;in&nbsp;the&nbsp;management&nbsp;of&nbsp;neutropenic&nbsp;children&nbsp;with&nbsp;fever&nbsp;suspected&nbsp;to&nbsp;be&nbsp;due&nbsp; to&nbsp;a&nbsp;bacterial&nbsp;infection.&nbsp;</p><p>Consideration&nbsp; should&nbsp; be&nbsp; given&nbsp; to&nbsp; official&nbsp; guidance&nbsp; on&nbsp; the&nbsp; appropriate&nbsp; use&nbsp; of&nbsp; antibacterial&nbsp; agents.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology&nbsp; </strong></p><p>The&nbsp;dose&nbsp;and&nbsp;frequency&nbsp;of&nbsp;Prizma&nbsp;depends&nbsp;on&nbsp;the&nbsp;severity&nbsp;and&nbsp;localisation&nbsp;of&nbsp;the&nbsp;infection&nbsp;and&nbsp; expected&nbsp;pathogens.&nbsp;</p><p><u>Adult&nbsp;and&nbsp;adolescent&nbsp;patients&nbsp;</u>&nbsp;</p><p><em>Infections</em>&nbsp;</p><p>The&nbsp;usual&nbsp;dose&nbsp;is&nbsp;4&nbsp;g&nbsp;piperacillin/0.5&nbsp;g&nbsp;tazobactam&nbsp;given&nbsp;every&nbsp;8&nbsp;hours.&nbsp;&nbsp;</p><p>For&nbsp;nosocomial&nbsp;pneumonia&nbsp;and&nbsp;bacterial&nbsp;infections&nbsp;in&nbsp;neutropenic&nbsp;patients,&nbsp;the&nbsp;recommended&nbsp;dose&nbsp;is&nbsp;4&nbsp;g&nbsp;piperacillin/0.5&nbsp;g&nbsp;tazobactam&nbsp;administered&nbsp;every&nbsp;6&nbsp;hours.&nbsp;This&nbsp;regimen&nbsp;may&nbsp;also&nbsp;be&nbsp; applicable&nbsp;to&nbsp;treat&nbsp;patients&nbsp;with&nbsp;other&nbsp;indicated&nbsp;infections&nbsp;when&nbsp;particularly&nbsp;severe.&nbsp;</p><p>The&nbsp;following&nbsp;table&nbsp;summarises&nbsp;the&nbsp;treatment&nbsp;frequency&nbsp;and&nbsp;the&nbsp;recommended&nbsp;dose&nbsp;for&nbsp;adult&nbsp; and&nbsp;adolescent&nbsp;patients&nbsp;by&nbsp;indication&nbsp;or&nbsp;condition:&nbsp;&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:167px"><p><strong>Treatment frequency</strong></p></td><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:396px"><p><strong>Prizma 4 g/0.5 g</strong></p></td></tr><tr><td rowspan="2" style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:167px"><p>Every 6 hours</p></td><td style="height:17.9pt; vertical-align:top; width:396px"><p>Severe pneumonia</p></td></tr><tr><td style="height:32.9pt; vertical-align:top; width:396px"><p>Neutropenic adults with fever suspected to be due to a bacterial infection.</p></td></tr><tr><td rowspan="3" style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:167px"><p>Every 8 hours</p></td><td style="height:17.9pt; vertical-align:top; width:396px"><p>Complicated urinary tract infections (including pyelonephritis)</p></td></tr><tr><td style="height:17.85pt; vertical-align:top; width:396px"><p>Complicated intra‐abdominal infections</p></td></tr><tr><td style="height:17.95pt; vertical-align:top; width:396px"><p>Skin and soft tissue infections (including diabetic foot infections</p></td></tr></tbody></table><p><em>Patients&nbsp;with&nbsp;renal&nbsp;impairment&nbsp;</em></p><p>The&nbsp;intravenous&nbsp; dose&nbsp; should&nbsp; be&nbsp;adjusted&nbsp; to&nbsp; the&nbsp; degree&nbsp; of&nbsp;actual&nbsp; renal&nbsp;impairment&nbsp;as&nbsp; follows&nbsp;(each&nbsp;patient&nbsp;must&nbsp;be&nbsp;monitored&nbsp; closely&nbsp;for&nbsp;signs&nbsp;of&nbsp;substance&nbsp;toxicity;&nbsp;medicinal&nbsp;product&nbsp;dose&nbsp; and&nbsp;interval&nbsp;should&nbsp;be&nbsp;adjusted&nbsp;accordingly):&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:154.7pt"><p><strong>Creatinine clearance (ml/min)</strong></p></td><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:268.35pt"><p><strong>Prizma (recommended dose)</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.8pt; vertical-align:top; width:154.7pt"><p>&gt; 40</p></td><td style="height:17.8pt; vertical-align:top; width:268.35pt"><p style="margin-left:1.45pt; margin-right:0in">&nbsp;&nbsp; No dose adjustment necessary</p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:154.7pt"><p>20‐40</p></td><td style="height:17.9pt; vertical-align:top; width:268.35pt"><p>Maximum dose suggested: 4 g/0.5 g every 8 hours</p></td></tr><tr><td style="border-color:#7a7a7a; height:17.95pt; vertical-align:top; width:154.7pt"><p>&lt; 20</p></td><td style="height:17.95pt; vertical-align:top; width:268.35pt"><p>Maximum dose suggested: 4 g/0.5 g every 12 hours</p></td></tr></tbody></table><p>For&nbsp;patients&nbsp;on&nbsp;haemodialysis,&nbsp;one&nbsp;additional&nbsp;dose&nbsp;of&nbsp;piperacillin/tazobactam&nbsp;2&nbsp;g/0.25&nbsp;g&nbsp;should&nbsp; be&nbsp; administered&nbsp; following&nbsp; each&nbsp; dialysis&nbsp; period,&nbsp; because&nbsp; haemodialysis&nbsp; removes&nbsp; 30%‐50%&nbsp; of&nbsp; piperacillin&nbsp;in&nbsp;4&nbsp;hours.&nbsp;&nbsp;</p><p><em>Patients&nbsp;with&nbsp;hepatic&nbsp;impairment&nbsp;</em></p><p>No&nbsp;dose&nbsp;adjustment&nbsp;is&nbsp;necessary&nbsp;(see&nbsp;section&nbsp;5.2).&nbsp;</p><p><em><u>Elderly&nbsp;patients</u>&nbsp;&nbsp; </em></p><p>No&nbsp; dose&nbsp; adjustment&nbsp; is&nbsp; required&nbsp; for&nbsp; the&nbsp; elderly&nbsp; with&nbsp; normal&nbsp; renal&nbsp; function&nbsp; or&nbsp; creatinine&nbsp; clearance&nbsp;values&nbsp;above&nbsp;40&nbsp;ml/min.&nbsp;</p><p><em><u>Paediatric&nbsp;population&nbsp;(2‐12&nbsp;years&nbsp;of&nbsp;age)</u>&nbsp;</em></p><p><em>Infections&nbsp;</em></p><p>The&nbsp; following&nbsp; table&nbsp; summarises&nbsp; the&nbsp; treatment&nbsp; frequency&nbsp; and&nbsp; the&nbsp; dose&nbsp; per&nbsp; body&nbsp; weight&nbsp; for&nbsp; paediatric&nbsp;patients&nbsp;2‐12&nbsp;years&nbsp;of&nbsp;age&nbsp;by&nbsp;indication&nbsp;or&nbsp;condition:&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:194.6pt"><p><strong>Dose per weight and treatment frequency</strong></p></td><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:228.4pt"><p><strong>Indication/condition</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:32.95pt; vertical-align:top; width:194.6pt"><p style="margin-left:1.4pt; margin-right:.25pt">80 mg Piperacillin/10 mg Tazobactam per kg body weight /every 6 hours</p></td><td style="height:32.95pt; vertical-align:top; width:228.4pt"><p>Neutropenic children with fever suspected to be due to bacterial infections*</p></td></tr><tr><td style="border-color:#7a7a7a; height:32.9pt; vertical-align:top; width:194.6pt"><p>100 mg Piperacillin/12.5 mg Tazobactam per kg body weight/every 8 hours</p></td><td style="height:32.9pt; vertical-align:top; width:228.4pt"><p>Complicated intra‐abdominal infections*</p></td></tr></tbody></table><p style="margin-right:0in">* Not to exceed the maximum 4 g/0.5 g per dose over 30 minutes.</p><p style="margin-right:0in"><em>Patients with renal impairment</em></p><p style="margin-right:16.4pt">The intravenous dose should be adjusted to the degree of actual renal impairment as follows (each patient must be monitored closely for signs of substance toxicity; medicinal product dose and interval should be adjusted accordingly):</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:238px"><p><strong>Creatinine clearance (ml/min)</strong></p></td><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:325px"><p style="margin-left:1.35pt; margin-right:0in"><strong>Prizma (recommended dose)</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.85pt; vertical-align:top; width:238px"><p>&gt; 50</p></td><td style="height:17.85pt; vertical-align:top; width:325px"><p style="margin-left:1.35pt; margin-right:0in">No dose adjustment needed.</p></td></tr><tr><td style="border-color:#7a7a7a; height:17.95pt; vertical-align:top; width:238px"><p>&le; 50</p></td><td style="height:17.95pt; vertical-align:top; width:325px"><p>70 mg piperacillin/ 8.75 mg tazobactam/kg every 8 hours.</p></td></tr></tbody></table><p style="margin-right:16.4pt; text-align:justify">For children on haemodialysis, one additional dose of 40 mg piperacillin/5 mg tazobactam/kg should be administered following each dialysis period.</p><p style="margin-right:16.4pt; text-align:justify"><em><u>Use&nbsp;in&nbsp;children&nbsp;aged&nbsp;below&nbsp;2&nbsp;years</u>&nbsp;&nbsp;</em></p><p style="margin-right:16.4pt">The&nbsp; safety&nbsp; and&nbsp; efficacy&nbsp; of&nbsp; piperacillin/tazobactam&nbsp; in&nbsp; children&nbsp; 0‐&nbsp; 2&nbsp; years&nbsp; of&nbsp; age&nbsp; has&nbsp; not&nbsp; been&nbsp; established.&nbsp;</p><p style="margin-right:16.4pt">No&nbsp;data&nbsp;from&nbsp;controlled&nbsp;clinical&nbsp;studies&nbsp;are&nbsp;available.&nbsp;</p><p style="margin-right:16.4pt"><strong>Treatment&nbsp;duration&nbsp;</strong></p><p style="margin-right:16.4pt">The&nbsp;usual&nbsp;duration&nbsp;of&nbsp;treatment&nbsp;for&nbsp;most&nbsp;indications&nbsp;is&nbsp;in&nbsp;the&nbsp;range&nbsp;of&nbsp;5‐14&nbsp;days.&nbsp;However,&nbsp;the&nbsp;duration&nbsp;of&nbsp;treatment&nbsp;should&nbsp;be &nbsp;guided&nbsp;by&nbsp;the&nbsp;severity&nbsp;of&nbsp;the&nbsp;infection,&nbsp;the&nbsp;pathogen(s)&nbsp;and&nbsp;the&nbsp; patient&#39;s&nbsp;clinical&nbsp;and&nbsp;bacteriological&nbsp;progress.&nbsp;</p><p style="margin-right:16.4pt"><strong>Method&nbsp;of&nbsp;administration&nbsp;</strong>&nbsp;</p><p style="margin-right:16.4pt">Prizma 4g/0.5 g&nbsp;is&nbsp;administered&nbsp;by&nbsp;intravenous&nbsp;infusion&nbsp;(over&nbsp;30&nbsp;minutes).&nbsp;&nbsp;</p><p style="margin-right:16.4pt">For&nbsp; instructions&nbsp; on&nbsp; reconstitution&nbsp; of&nbsp; the&nbsp;medicinal&nbsp; product&nbsp; before&nbsp;administration,&nbsp; see&nbsp; section&nbsp; 6.6.&nbsp; <strong>&nbsp; </strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, any other penicillin‐antibacterial agent or to any of the excipients listed in section 6.1. 
History  of  acute  severe  allergic  reaction  to  any  other  beta‐lactam  active  substances  (e.g. cephalosporin, monobactam or carbapenem).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The&nbsp;selection&nbsp;of&nbsp;piperacillin/tazobactam&nbsp;to&nbsp;treat&nbsp;an&nbsp;individual&nbsp;patient&nbsp;should&nbsp;take&nbsp;into&nbsp;account&nbsp;the&nbsp; appropriateness&nbsp;of&nbsp;using&nbsp;a&nbsp;broad‐spectrum&nbsp;semi‐synthetic&nbsp;penicillin&nbsp;based&nbsp;on&nbsp; factors&nbsp;such&nbsp;as&nbsp;the&nbsp; severity&nbsp;of&nbsp;the&nbsp;infection&nbsp;and&nbsp;the&nbsp;prevalence&nbsp;of&nbsp;resistance&nbsp;to&nbsp;other&nbsp;suitable&nbsp;antibacterial&nbsp;agents.&nbsp;</p><p>Before&nbsp;initiating&nbsp;therapy&nbsp;with&nbsp;piperacillin/tazobactam,&nbsp;careful&nbsp;inquiry&nbsp;should&nbsp;be&nbsp;made&nbsp;concerning&nbsp; previous&nbsp; hypersensitivity&nbsp; reactions&nbsp; to&nbsp; penicillins,&nbsp; other&nbsp; beta‐lactam&nbsp; agents&nbsp; (e.g.&nbsp; cephalosporin,&nbsp; monobactam&nbsp;or&nbsp;carbapenem)&nbsp;and&nbsp;other&nbsp;allergens.&nbsp;Serious&nbsp;and&nbsp;occasionally&nbsp; fatal&nbsp;hypersensitivity&nbsp; (anaphylactic/anaphylactoid&nbsp;[including&nbsp;shock])&nbsp;reactions&nbsp;have&nbsp;been&nbsp;reported&nbsp;in&nbsp;patients&nbsp;receiving&nbsp;therapy&nbsp;with&nbsp;penicillins,&nbsp;including&nbsp;piperacillin/tazobactam.&nbsp;These&nbsp;reactions&nbsp;are&nbsp;more&nbsp;likely&nbsp;to&nbsp;occur&nbsp; in&nbsp; persons&nbsp; with&nbsp; a&nbsp; history&nbsp; of&nbsp; sensitivity&nbsp; to&nbsp; multiple&nbsp; allergens.&nbsp; Serious&nbsp; hypersensitivity&nbsp; reactions&nbsp; require&nbsp; the&nbsp; discontinuation&nbsp;of&nbsp; the&nbsp;antibiotic,&nbsp;and&nbsp;may&nbsp; require&nbsp;administration&nbsp; of&nbsp;epinephrine&nbsp;and&nbsp; other&nbsp;emergency&nbsp;measures.&nbsp;</p><p>Piperacillin/tazobactam&nbsp;may&nbsp;cause&nbsp;severe&nbsp;cutaneous&nbsp;adverse&nbsp; reactions,&nbsp; such&nbsp;as&nbsp;Stevens‐Johnson&nbsp;syndrome,&nbsp;toxic&nbsp;epidermal&nbsp;necrolysis,&nbsp;drug&nbsp;reaction &nbsp;with&nbsp;eosinophilia&nbsp;and&nbsp;systemic&nbsp;symptoms,&nbsp;and&nbsp; acute&nbsp;generalised&nbsp;exanthematous&nbsp;pustulosis&nbsp;(see&nbsp;section&nbsp;4.8).&nbsp;If&nbsp;patients&nbsp;develop&nbsp;a&nbsp;skin&nbsp;rash&nbsp;they&nbsp; should&nbsp;be&nbsp;monitored&nbsp;closely&nbsp;and&nbsp;piperacillin/tazobactam&nbsp;discontinued&nbsp;if&nbsp;lesions&nbsp;progress.&nbsp;</p><p>Antibiotic‐induced&nbsp;pseudomembranous&nbsp;colitis&nbsp;may&nbsp;be&nbsp;manifested&nbsp;by&nbsp;severe,&nbsp;persistent&nbsp;diarrhoea&nbsp; which&nbsp; may&nbsp; be&nbsp; life‐threatening.&nbsp; The&nbsp; onset&nbsp; of&nbsp; pseudomembranous&nbsp; colitis&nbsp; symptoms&nbsp; may&nbsp; occur&nbsp; during&nbsp; or&nbsp; after&nbsp; antibacterial&nbsp; treatment.&nbsp; In&nbsp; these&nbsp; cases&nbsp; piperacillin/tazobactam,&nbsp; should&nbsp; be&nbsp; discontinued.&nbsp;</p><p>Therapy&nbsp;with&nbsp;piperacillin/tazobactam&nbsp;may&nbsp;result&nbsp;in&nbsp;the&nbsp;emergence&nbsp;of&nbsp;resistant&nbsp;organisms,&nbsp;which&nbsp;&nbsp; might&nbsp;cause&nbsp;super‐infections.&nbsp;</p><p>Bleeding&nbsp;manifestations&nbsp; have&nbsp; occurred&nbsp; in&nbsp; some&nbsp; patients&nbsp; receiving&nbsp; beta‐lactam&nbsp;antibiotics.&nbsp;These&nbsp;reactions&nbsp;sometimes&nbsp;have&nbsp;been&nbsp;associated &nbsp;with&nbsp;abnormalities&nbsp;of&nbsp;coagulation&nbsp;tests,&nbsp;such&nbsp;as&nbsp;clotting&nbsp; time,&nbsp; platelet&nbsp; aggregation&nbsp; and&nbsp; prothrombin&nbsp; time,&nbsp; and&nbsp; are&nbsp; more&nbsp; likely&nbsp; to&nbsp; occur&nbsp; in&nbsp; patients&nbsp; with&nbsp; renal&nbsp; failure.&nbsp; If&nbsp; bleeding&nbsp; manifestations&nbsp; occur,&nbsp; the&nbsp; antibiotic&nbsp; should&nbsp; be&nbsp; discontinued&nbsp; and&nbsp; appropriate&nbsp;therapy&nbsp;instituted.&nbsp;</p><p>Leukopenia&nbsp;and&nbsp;neutropenia&nbsp;may&nbsp;occur,&nbsp;especially&nbsp;during&nbsp;prolonged&nbsp; therapy;&nbsp; therefore,&nbsp;periodic&nbsp;assessment&nbsp;of&nbsp;haematopoietic&nbsp;function &nbsp;should&nbsp;be&nbsp;performed.&nbsp;</p><p>As&nbsp; with&nbsp; treatment&nbsp; with&nbsp; other&nbsp; penicillins,&nbsp; neurological&nbsp; complications&nbsp; in&nbsp; the&nbsp; form&nbsp; of&nbsp; convulsions&nbsp;(seizures)&nbsp;may&nbsp;occur&nbsp;when&nbsp;high &nbsp;doses&nbsp;are&nbsp;administered,&nbsp;especially&nbsp;in&nbsp;patients&nbsp;with&nbsp;impaired&nbsp;renal&nbsp; function&nbsp;(see&nbsp;section&nbsp;4.8).&nbsp;</p><p>Prizma&nbsp; contains&nbsp; sodium.&nbsp; Each&nbsp; vial&nbsp; contains&nbsp; 216.1&nbsp; mg&nbsp; sodium.&nbsp; This&nbsp; should&nbsp; be&nbsp; taken&nbsp; into&nbsp; consideration&nbsp;for&nbsp;patients&nbsp;who&nbsp;are&nbsp;on&nbsp;a&nbsp;controlled‐sodium&nbsp;diet.</p><p>Hypokalaemia&nbsp;may&nbsp;occur&nbsp;in&nbsp;patients&nbsp;with&nbsp;low&nbsp;potassium&nbsp;reserves&nbsp;or&nbsp;those&nbsp;receiving&nbsp;concomitant&nbsp; medicinal&nbsp;products&nbsp;that&nbsp;may&nbsp;lower&nbsp;potassium &nbsp;levels;&nbsp;periodic&nbsp;electrolyte&nbsp;determinations&nbsp;may&nbsp;be&nbsp; advisable&nbsp;in&nbsp;such&nbsp;patients.&nbsp;</p><p><u>Renal&nbsp;Impairment&nbsp;</u>&nbsp;</p><p>Due&nbsp;to&nbsp;its&nbsp;potential&nbsp;nephrotoxicity&nbsp; (see&nbsp;section&nbsp;4.8),&nbsp;piperacillin/tazobactam&nbsp;should&nbsp;be&nbsp;used&nbsp;with&nbsp; care&nbsp; in&nbsp; patients&nbsp; with&nbsp; renal&nbsp; impairment&nbsp; or&nbsp; in&nbsp; hemodialysis&nbsp; patients.&nbsp; Intravenous&nbsp; dosages&nbsp; and&nbsp; administration&nbsp; intervals&nbsp; should&nbsp; be&nbsp; adjusted&nbsp; to&nbsp; the&nbsp; degree&nbsp; of&nbsp; renal&nbsp; function&nbsp; impairment&nbsp; (see&nbsp; section&nbsp;4.2).</p><p>&nbsp; In&nbsp; a&nbsp; secondary&nbsp; analysis&nbsp; using&nbsp; data&nbsp; from&nbsp; a&nbsp; large&nbsp; multicenter,&nbsp; randomized‐controlled&nbsp; trial&nbsp; when&nbsp;glomerular&nbsp;filtration&nbsp;rate&nbsp;(GFR)&nbsp; was&nbsp;examined&nbsp;after&nbsp;administration&nbsp;of&nbsp;frequently&nbsp;used&nbsp;antibiotics&nbsp;in&nbsp; critically&nbsp; ill&nbsp; patients,&nbsp; the&nbsp; use&nbsp; of&nbsp; piperacillin/tazobactam&nbsp; was&nbsp; associated&nbsp; with&nbsp; a&nbsp; lower&nbsp; rate&nbsp; of&nbsp; reversible&nbsp; GFR&nbsp; improvement&nbsp; compared&nbsp; with&nbsp; the&nbsp; other&nbsp; antibiotics.&nbsp; This&nbsp; secondary&nbsp; analysis&nbsp;concluded&nbsp;that&nbsp;piperacillin/tazobactam &nbsp;was&nbsp;a&nbsp;cause&nbsp;of&nbsp;delayed&nbsp;renal&nbsp;recovery&nbsp;in&nbsp;these&nbsp;patients.</p><p>&nbsp; Combined&nbsp; use&nbsp; of&nbsp; piperacillin/tazobactam&nbsp; and&nbsp; vancomycin&nbsp; may&nbsp; be&nbsp; associated&nbsp; with&nbsp; an&nbsp; increased&nbsp;incidence&nbsp;of&nbsp;acute&nbsp;kidney&nbsp;injury&nbsp;(see&nbsp;section&nbsp;4.5).</p><p>&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Non‐depolarising&nbsp;muscle&nbsp;relaxants</u>&nbsp;&nbsp;</p><p>Piperacillin&nbsp;when&nbsp;used&nbsp;concomitantly&nbsp;with&nbsp;vecuronium&nbsp;has&nbsp;been&nbsp;implicated&nbsp;in&nbsp;the&nbsp;prolongation&nbsp;of&nbsp; the&nbsp; neuromuscular&nbsp; blockade&nbsp; of&nbsp; vecuronium.&nbsp; Due&nbsp; to&nbsp; their&nbsp; similar&nbsp; mechanisms&nbsp; of&nbsp; action,&nbsp; it&nbsp; is&nbsp; expected&nbsp; that&nbsp; the&nbsp; neuromuscular&nbsp; blockade&nbsp; produced&nbsp; by&nbsp; any&nbsp; of&nbsp; the&nbsp; non‐depolarising&nbsp; muscle&nbsp; relaxants&nbsp;could&nbsp;be&nbsp;prolonged&nbsp;in&nbsp;the&nbsp;presence&nbsp;of&nbsp;piperacillin.&nbsp;</p><p><u>Anticoagulants</u>&nbsp;&nbsp;</p><p>During&nbsp;simultaneous&nbsp;administration&nbsp;of&nbsp;heparin,&nbsp;oral&nbsp;anticoagulants&nbsp;and&nbsp;other&nbsp;substances&nbsp;that&nbsp;may&nbsp;affect&nbsp;the&nbsp;blood&nbsp;coagulation&nbsp;system&nbsp;including&nbsp; thrombocyte&nbsp;function,&nbsp;appropriate&nbsp;coagulation&nbsp;tests&nbsp; should&nbsp;be&nbsp;performed&nbsp;more&nbsp;frequently&nbsp;and&nbsp;monitored&nbsp;regularly.&nbsp;</p><p><u>Methotrexate</u>&nbsp;&nbsp;</p><p>Piperacillin&nbsp; may&nbsp; reduce&nbsp; the&nbsp; excretion&nbsp; of&nbsp; methotrexate;&nbsp; therefore,&nbsp; serum&nbsp; levels&nbsp; of&nbsp; methotrexate&nbsp;should&nbsp;be&nbsp;monitored&nbsp;in&nbsp;patients&nbsp;</p><p>to&nbsp;avoid&nbsp;substance&nbsp;toxicity.&nbsp;</p><p><u>Probenecid&nbsp;</u>&nbsp;</p><p>As&nbsp; with&nbsp; other&nbsp; penicillins,&nbsp; concurrent&nbsp; administration&nbsp; of&nbsp; probenecid&nbsp; and&nbsp; piperacillin/tazobactam&nbsp; produces&nbsp; a&nbsp; longer&nbsp; half‐life&nbsp; and&nbsp; lower&nbsp; renal&nbsp; clearance&nbsp; for&nbsp; both&nbsp; piperacillin&nbsp; and&nbsp; tazobactam;&nbsp; however,&nbsp;peak&nbsp;plasma&nbsp;concentrations&nbsp;of&nbsp;either&nbsp;substances&nbsp;are&nbsp;unaffected.&nbsp;&nbsp;</p><p><u>Aminoglycosides</u>&nbsp;&nbsp;</p><p>Piperacillin,&nbsp; either&nbsp; alone&nbsp; or&nbsp; with&nbsp; tazobactam,&nbsp; did&nbsp; not&nbsp; significantly&nbsp; alter&nbsp; the&nbsp; pharmacokinetics&nbsp; of&nbsp; tobramycin&nbsp;in&nbsp; subjects&nbsp;with&nbsp;normal&nbsp; renal&nbsp; function&nbsp;and&nbsp;with&nbsp;mild&nbsp;or&nbsp;moderate&nbsp; renal&nbsp;impairment.&nbsp; The&nbsp; pharmacokinetics&nbsp; of&nbsp; piperacillin,&nbsp; tazobactam,&nbsp; and&nbsp; the&nbsp; M1&nbsp; metabolite&nbsp; were&nbsp; also&nbsp; not&nbsp; significantly&nbsp;altered&nbsp;by&nbsp;tobramycin&nbsp;administration.&nbsp;</p><p>The&nbsp;inactivation&nbsp;of&nbsp;tobramycin&nbsp;and&nbsp;gentamicin&nbsp;by&nbsp;piperacillin&nbsp;has&nbsp;been&nbsp;demonstrated&nbsp;in&nbsp;patients&nbsp; with&nbsp;severe&nbsp;renal&nbsp;impairment.&nbsp;&nbsp;</p><p>For&nbsp; information&nbsp; related&nbsp; to&nbsp; the&nbsp; administration&nbsp; of&nbsp; piperacillin/tazobactam&nbsp; with&nbsp; aminoglycosides&nbsp; please&nbsp;refer&nbsp;to&nbsp;sections&nbsp;6.2&nbsp;and&nbsp;6.6.&nbsp;&nbsp;</p><p><u>Vancomycin</u>&nbsp;&nbsp;</p><p>Studies&nbsp; have&nbsp; detected&nbsp; an&nbsp; increased&nbsp; incidence&nbsp; of&nbsp; acute&nbsp; kidney&nbsp; injury&nbsp; in&nbsp; patients&nbsp; concomitantly&nbsp; administered&nbsp; piperacillin/tazobactam&nbsp; and&nbsp; vancomycin&nbsp; as&nbsp; compared&nbsp; to&nbsp; vancomycin&nbsp; alone&nbsp; (see&nbsp; section&nbsp; 4.4).&nbsp; Some&nbsp; of&nbsp; these&nbsp; studies&nbsp; have&nbsp; reported&nbsp; that&nbsp; the&nbsp; interaction&nbsp; is&nbsp; vancomycin&nbsp; dose‐ dependent.</p><p>&nbsp; No&nbsp; pharmacokinetic&nbsp; interactions&nbsp; have&nbsp; been&nbsp; noted&nbsp; between&nbsp; piperacillin/tazobactam&nbsp; and&nbsp; vancomycin.&nbsp;</p><p><u>Effects&nbsp;on&nbsp;laboratory&nbsp;tests&nbsp; </u></p><p>Non‐enzymatic&nbsp;methods&nbsp; of&nbsp;measuring&nbsp; urinary&nbsp; glucose&nbsp;may&nbsp;lead&nbsp; to&nbsp;false‐positive&nbsp; results,&nbsp;as&nbsp;with&nbsp; other&nbsp; penicillins.&nbsp; Therefore,&nbsp; enzymatic&nbsp; urinary&nbsp; glucose&nbsp; measurement&nbsp; is&nbsp; required&nbsp; under&nbsp; piperacillin/tazobactam&nbsp;therapy.&nbsp;</p><p>A&nbsp; number&nbsp; of&nbsp; chemical&nbsp; urine&nbsp; protein&nbsp; measurement&nbsp; methods&nbsp; may&nbsp; lead&nbsp; to&nbsp; false‐positive&nbsp; results.&nbsp;</p><p>Protein&nbsp;measurement&nbsp;with&nbsp;dip&nbsp;sticks&nbsp;is&nbsp;not&nbsp;affected.&nbsp;&nbsp;</p><p>The&nbsp;direct&nbsp;Coombs&nbsp;test&nbsp;may&nbsp;be&nbsp;positive.&nbsp;</p><p>Bio‐Rad&nbsp; Laboratories&nbsp; <em>Platelia&nbsp; Aspergillus&nbsp;</em> EIA&nbsp; tests&nbsp; may&nbsp; lead&nbsp; to&nbsp; false‐positive&nbsp; results&nbsp; for&nbsp; patients&nbsp; receiving&nbsp; piperacillin/tazobactam.&nbsp; Cross‐reactions&nbsp; with&nbsp; non‐Aspergillus&nbsp; polysaccharides&nbsp; and&nbsp; polyfuranoses&nbsp;with&nbsp;Bio‐Rad&nbsp;Laboratories&nbsp;<em>Platelia&nbsp;Aspergillus</em>&nbsp;EIA&nbsp;test&nbsp;have&nbsp;been&nbsp;reported.&nbsp;&nbsp;</p><p>Positive&nbsp;test&nbsp;results&nbsp;for&nbsp;the&nbsp;assays&nbsp;listed&nbsp;above&nbsp;in&nbsp;patients&nbsp;receiving&nbsp;piperacillin/tazobactam&nbsp;should&nbsp; be&nbsp;confirmed&nbsp;by&nbsp;other&nbsp;diagnostic&nbsp;methods.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u>&nbsp;&nbsp;</p><p>There are&nbsp;no or&nbsp;a limited&nbsp; amount&nbsp; of&nbsp; data&nbsp; from&nbsp; the&nbsp; use&nbsp; of&nbsp; piperacillin/tazobactam&nbsp; in&nbsp; pregnant&nbsp; women.&nbsp;&nbsp;</p><p>Studies&nbsp;in&nbsp;animals&nbsp;have&nbsp;shown&nbsp;developmental&nbsp;toxicity,&nbsp;but&nbsp;no&nbsp;evidence&nbsp;of&nbsp;teratogenicity,&nbsp;at&nbsp;doses&nbsp; that&nbsp;are&nbsp;maternally&nbsp;toxic&nbsp;(see&nbsp;section&nbsp;5.3).&nbsp;&nbsp;</p><p>Piperacillin&nbsp;and&nbsp;tazobactam&nbsp;cross&nbsp;the&nbsp;placenta.&nbsp;Piperacillin/tazobactam&nbsp;should&nbsp;only&nbsp;be&nbsp;used&nbsp;during&nbsp;pregnancy&nbsp;if&nbsp;clearly&nbsp;indicated,&nbsp;i.e.&nbsp;only&nbsp;if&nbsp;the</p><p>&nbsp;expected&nbsp;benefit&nbsp;outweighs&nbsp;the&nbsp;possible&nbsp;risks&nbsp;to&nbsp;the&nbsp; pregnant&nbsp;woman&nbsp;and&nbsp;foetus.&nbsp;</p><p><u>Breast‐feeding&nbsp;&nbsp;</u></p><p>Piperacillin&nbsp;is&nbsp;excreted&nbsp;in&nbsp;low&nbsp;concentrations&nbsp;in&nbsp;human&nbsp;milk;&nbsp;tazobactam&nbsp;concentrations&nbsp;in&nbsp;human&nbsp; milk&nbsp;have&nbsp;not&nbsp;been&nbsp;studied.&nbsp;Women&nbsp;who&nbsp;are&nbsp;breast‐feeding&nbsp;should&nbsp;be&nbsp;treated&nbsp;only&nbsp;if&nbsp;the&nbsp;expected&nbsp; benefit&nbsp;outweighs&nbsp;the&nbsp;possible&nbsp;risks&nbsp;to&nbsp;the&nbsp;woman&nbsp;and&nbsp;child.&nbsp;</p><p><u>Fertility</u>&nbsp;&nbsp;</p><p>A&nbsp;fertility&nbsp;study&nbsp;in&nbsp;rats&nbsp;showed&nbsp;no&nbsp;effect&nbsp;on&nbsp;fertility&nbsp;and&nbsp;mating&nbsp;after&nbsp;intraperitoneal&nbsp;administration&nbsp;of&nbsp;tazobactam&nbsp;or&nbsp;the&nbsp;combination&nbsp;piperacillin/</p><p>tazobactam&nbsp;(see&nbsp;section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No&nbsp;studies&nbsp;on&nbsp;the&nbsp;effect&nbsp;on&nbsp;the&nbsp;ability&nbsp;to&nbsp;drive&nbsp;and&nbsp;use&nbsp;machines&nbsp;have&nbsp;been&nbsp;performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The&nbsp;most&nbsp;commonly&nbsp;reported&nbsp;adverse&nbsp;reaction&nbsp;is&nbsp;diarrhoea&nbsp;(occurring&nbsp;in&nbsp;1&nbsp;patient&nbsp;out&nbsp;of&nbsp;10).&nbsp;</p><p>Among&nbsp; the&nbsp; most&nbsp; serious&nbsp; adverse&nbsp; reactions&nbsp; pseudo‐membranous&nbsp; colitis&nbsp; and&nbsp; toxic&nbsp; epidermal&nbsp; necrolysis&nbsp; occur&nbsp; in&nbsp; 1&nbsp; to&nbsp; 10&nbsp; patients&nbsp; in&nbsp; 10,000.&nbsp; The&nbsp; frequencies&nbsp; for&nbsp; pancytopenia,&nbsp; anaphylactic&nbsp; shock&nbsp;and&nbsp;Stevens‐Johnson&nbsp;syndrome&nbsp;cannot&nbsp;be&nbsp;estimated&nbsp;from&nbsp;the&nbsp;currently&nbsp;available&nbsp;data.&nbsp;</p><p>In&nbsp; the&nbsp; following&nbsp; table,&nbsp;adverse&nbsp; reactions&nbsp;are&nbsp;listed&nbsp;by&nbsp;system&nbsp;organ&nbsp;class&nbsp;and&nbsp;MedDRA‐preferred&nbsp; term.&nbsp;Within&nbsp;each&nbsp; frequency&nbsp; grouping,&nbsp; undesirable&nbsp;effects&nbsp; are&nbsp; presented&nbsp; in&nbsp; order&nbsp; of&nbsp; decreasing&nbsp; seriousness.</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#7a7a7a; height:39.75pt; vertical-align:top; width:140px"><p style="margin-left:1.4pt; margin-right:-1.0pt"><strong>System Organ </strong><strong>Class</strong></p></td><td style="border-color:#7a7a7a; height:39.75pt; vertical-align:top; width:121px"><p style="margin-left:1.4pt; margin-right:2.9pt"><strong>Very common</strong></p><p><strong>(&ge; 1/10)</strong></p></td><td style="border-color:#7a7a7a; height:39.75pt; vertical-align:top; width:129px"><p style="margin-left:1.45pt; margin-right:0in"><strong>Common</strong></p><p style="margin-left:1.45pt; margin-right:0in"><strong>(&ge; 1/100 to &lt; 1/10)</strong></p></td><td style="border-color:#7a7a7a; height:39.75pt; vertical-align:top; width:125px"><p style="margin-left:1.45pt; margin-right:0in"><strong>Uncommon</strong></p><p style="margin-left:1.45pt; margin-right:12.3pt"><strong>(&ge; 1/1,000 to &lt; </strong><strong>1/100)</strong></p></td><td style="border-color:#7a7a7a; height:39.75pt; vertical-align:top; width:117px"><p style="margin-left:1.5pt; margin-right:0in"><strong>Rare</strong></p><p style="margin-left:1.5pt; margin-right:0in"><strong>(&ge; 1/10,000 to</strong></p><p style="margin-left:1.5pt; margin-right:0in"><strong>&lt; 1/1,000)</strong></p></td><td style="border-color:#7a7a7a; height:39.75pt; vertical-align:top; width:151px"><p style="margin-left:1.5pt; margin-right:4.8pt"><strong>Frequency not known (cannot be estimated</strong></p><p style="margin-left:1.5pt"><strong>from available data)</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:39.75pt; vertical-align:top; width:140px"><p style="margin-left:1.4pt; margin-right:-1.0pt"><strong>Infections and </strong><strong>infestations</strong></p></td><td style="height:39.75pt; vertical-align:top; width:121px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:39.75pt; vertical-align:top; width:129px"><p style="margin-left:1.45pt; margin-right:0in">candida infection *</p></td><td style="height:39.75pt; vertical-align:top; width:125px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:39.75pt; vertical-align:top; width:117px"><p style="margin-left:1.5pt; margin-right:9.1pt; text-indent:-.1pt">pseudo‐ membranous</p><p style="margin-left:1.5pt">colitis</p></td><td style="height:39.75pt; vertical-align:top; width:151px"><p style="margin-left:0in">&nbsp;</p></td></tr><tr><td style="border-color:#7a7a7a; height:64.25pt; vertical-align:top; width:140px"><p style="margin-left:1.4pt; margin-right:-1.0pt"><strong>Blood and lymphatic system disorders</strong></p></td><td style="height:64.25pt; vertical-align:top; width:121px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:64.25pt; vertical-align:top; width:129px"><p style="margin-left:1.45pt; margin-right:0in">thrombocytopenia, anaemia*</p></td><td style="height:64.25pt; vertical-align:top; width:125px"><p style="margin-left:1.45pt; margin-right:0in">leukopenia</p></td><td style="height:64.25pt; vertical-align:top; width:117px"><p>agranulocytosis</p></td><td style="height:64.25pt; vertical-align:top; width:151px"><p style="margin-left:1.5pt; margin-right:0in; text-indent:-.1pt">pancytopenia*, neutropenia, haemolytic anaemia*, thrombocytosis*,</p><p style="margin-left:1.5pt">eosinophilia*</p></td></tr><tr><td style="border-color:#7a7a7a; height:76.6pt; vertical-align:top; width:140px"><p style="margin-left:1.4pt; margin-right:-1.0pt"><strong>Immune system </strong><strong>disorders</strong></p></td><td style="height:76.6pt; vertical-align:top; width:121px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:76.6pt; vertical-align:top; width:129px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:76.6pt; vertical-align:top; width:125px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:76.6pt; vertical-align:top; width:117px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:76.6pt; vertical-align:top; width:151px"><p style="margin-left:1.5pt; margin-right:4.5pt">anaphylactoid shock*, anaphylactic shock*, anaphylactoid reaction*, anaphylactic reaction*,</p><p style="margin-left:1.5pt">hypersensitivity*</p></td></tr><tr><td style="border-color:#7a7a7a; height:39.75pt; vertical-align:top; width:140px"><p style="margin-left:1.4pt; margin-right:3.5pt"><strong>Metabolism and </strong><strong>nutrition disorders</strong></p></td><td style="height:39.75pt; vertical-align:top; width:121px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:39.75pt; vertical-align:top; width:129px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:39.75pt; vertical-align:top; width:125px"><p style="margin-left:1.45pt; margin-right:0in">hypokalaemia</p></td><td style="height:39.75pt; vertical-align:top; width:117px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:39.75pt; vertical-align:top; width:151px"><p style="margin-left:0in">&nbsp;</p></td></tr><tr><td style="border-color:#7a7a7a; height:27.4pt; vertical-align:top; width:140px"><p style="margin-right:-1.0pt"><strong>Psychiatric </strong><strong>disorders</strong></p></td><td style="height:27.4pt; vertical-align:top; width:121px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:27.4pt; vertical-align:top; width:129px"><p style="margin-left:1.45pt; margin-right:0in">insomnia</p></td><td style="height:27.4pt; vertical-align:top; width:125px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:27.4pt; vertical-align:top; width:117px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:27.4pt; vertical-align:top; width:151px"><p style="margin-left:1.45pt; margin-right:0in">delirium*</p></td></tr><tr><td style="border-color:#7a7a7a; height:27.5pt; vertical-align:top; width:140px"><p style="margin-left:1.4pt; margin-right:-1.0pt"><strong>Nervous system </strong><strong>disorders</strong></p></td><td style="height:27.5pt; vertical-align:top; width:121px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:27.5pt; vertical-align:top; width:129px"><p style="margin-left:1.45pt; margin-right:0in">headache</p></td><td style="height:27.5pt; vertical-align:top; width:125px"><p>seizure*</p></td><td style="height:27.5pt; vertical-align:top; width:117px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:27.5pt; vertical-align:top; width:151px"><p style="margin-left:0in">&nbsp;</p></td></tr><tr><td style="border-color:#7a7a7a; height:52.05pt; vertical-align:top; width:140px"><p style="margin-left:1.4pt; margin-right:3.5pt"><strong>Vascular </strong><strong>disorders</strong></p></td><td style="height:52.05pt; vertical-align:top; width:121px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:52.05pt; vertical-align:top; width:129px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:52.05pt; vertical-align:top; width:125px"><p style="margin-left:1.45pt; margin-right:0in">hypotension, phlebitis,</p><p style="margin-left:1.45pt">thrombophlebitis, flushing</p></td><td style="height:52.05pt; vertical-align:top; width:117px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:52.05pt; vertical-align:top; width:151px"><p style="margin-left:0in">&nbsp;</p></td></tr><tr><td style="border-color:#7a7a7a; height:51.95pt; vertical-align:top; width:140px"><p style="margin-left:1.4pt; margin-right:18.05pt; text-align:justify"><strong>Respiratory,&nbsp;</strong><strong>thoracic and mediastinal</strong></p><p><strong>disorders</strong></p></td><td style="height:51.95pt; vertical-align:top; width:121px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:51.95pt; vertical-align:top; width:129px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:51.95pt; vertical-align:top; width:125px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:51.95pt; vertical-align:top; width:117px"><p style="margin-left:1.5pt; margin-right:0in">epistaxis</p></td><td style="height:51.95pt; vertical-align:top; width:151px"><p style="margin-left:1.45pt; margin-right:0in">eosinophilic pneumonia</p></td></tr><tr><td style="border-color:#7a7a7a; height:39.8pt; vertical-align:top; width:140px"><p style="margin-left:1.4pt; margin-right:-1.0pt"><strong>Gastrointestinal </strong><strong>disorders</strong></p></td><td style="height:39.8pt; vertical-align:top; width:121px"><p>diarrhoea</p></td><td style="height:39.8pt; vertical-align:top; width:129px"><p style="margin-left:1.5pt; margin-right:0in">abdominal pain, vomiting,</p><p style="margin-left:1.45pt; margin-right:0in">constipation, nausea, dyspepsia</p></td><td style="height:39.8pt; vertical-align:top; width:125px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:39.8pt; vertical-align:top; width:117px"><p style="margin-left:1.5pt; margin-right:0in">stomatitis</p></td><td style="height:39.8pt; vertical-align:top; width:151px"><p style="margin-left:0in">&nbsp;</p></td></tr><tr><td style="border-color:#7a7a7a; height:27.45pt; vertical-align:top; width:140px"><p style="margin-left:1.4pt; margin-right:-1.0pt"><strong>Hepatobiliary </strong><strong>disorders</strong></p></td><td style="height:27.45pt; vertical-align:top; width:121px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:27.45pt; vertical-align:top; width:129px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:27.45pt; vertical-align:top; width:125px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:27.45pt; vertical-align:top; width:117px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:27.45pt; vertical-align:top; width:151px"><p style="margin-left:1.5pt; margin-right:0in">hepatitis*, jaundice</p></td></tr><tr><td style="border-color:#7a7a7a; height:150.3pt; vertical-align:top; width:140px"><p style="margin-left:1.4pt; margin-right:-1.0pt"><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="height:150.3pt; vertical-align:top; width:121px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:150.3pt; vertical-align:top; width:129px"><p style="margin-left:1.45pt; margin-right:0in">rash, pruritus</p></td><td style="height:150.3pt; vertical-align:top; width:125px"><p style="margin-left:1.45pt; margin-right:0in; text-indent:-.05pt">erythema multiforme*, urticaria, rash maculopapular*</p></td><td style="height:150.3pt; vertical-align:top; width:117px"><p style="margin-left:1.5pt; margin-right:-.95pt">toxic epidermal necrolysis*</p></td><td style="height:150.3pt; vertical-align:top; width:151px"><p style="margin-left:1.5pt; margin-right:0in">Stevens‐Johnson syndrome*, dermatitis exfoliative, drug reaction with eosinophilia and systemic symptoms (DRESS)<sup>*</sup>, acute generalised exanthematous pustulosis (AGEP)<sup>*</sup>,</p><p style="margin-left:1.5pt; margin-right:4.8pt">dermatitis bullous, purpura</p></td></tr><tr><td style="border-color:#7a7a7a; height:39.75pt; vertical-align:top; width:140px"><p><strong>Musculoskeletal</strong></p><p style="margin-left:1.4pt; margin-right:-1.0pt"><strong>and connective </strong><strong>tissue disorders</strong></p></td><td style="height:39.75pt; vertical-align:top; width:121px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:39.75pt; vertical-align:top; width:129px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:39.75pt; vertical-align:top; width:125px"><p style="margin-left:1.45pt; margin-right:0in">arthralgia, myalgia</p></td><td style="height:39.75pt; vertical-align:top; width:117px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:39.75pt; vertical-align:top; width:151px"><p style="margin-left:0in">&nbsp;</p></td></tr><tr><td style="border-color:#7a7a7a; height:39.7pt; vertical-align:top; width:140px"><p style="margin-left:1.4pt; margin-right:1.0pt"><strong>Renal and urinary disorders</strong></p></td><td style="height:39.7pt; vertical-align:top; width:121px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:39.7pt; vertical-align:top; width:129px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:39.7pt; vertical-align:top; width:125px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:39.7pt; vertical-align:top; width:117px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:39.7pt; vertical-align:top; width:151px"><p style="margin-left:1.5pt; margin-right:28.1pt">renal failure, tubulointerstitial nephritis*</p></td></tr><tr><td style="border-color:#7a7a7a; height:52pt; vertical-align:top; width:140px"><p style="margin-left:1.4pt; margin-right:-1.0pt"><strong>General disorders and administration site conditions</strong></p></td><td style="height:52pt; vertical-align:top; width:121px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:52pt; vertical-align:top; width:129px"><p style="margin-left:1.45pt; margin-right:14.5pt">pyrexia, injection site reaction</p></td><td style="height:52pt; vertical-align:top; width:125px"><p style="margin-left:1.45pt; margin-right:0in">chills</p></td><td style="height:52pt; vertical-align:top; width:117px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:52pt; vertical-align:top; width:151px"><p style="margin-left:0in">&nbsp;</p></td></tr><tr><td style="border-color:#7a7a7a; height:174.95pt; vertical-align:top; width:140px"><p><strong>Investigations</strong></p></td><td style="height:174.95pt; vertical-align:top; width:121px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:174.95pt; vertical-align:top; width:129px"><p style="margin-left:1.45pt; margin-right:-.9pt">alanine aminotransferase increased, aspartate aminotransferase increased, protein total decreased, blood albumin decreased, Coombs direct test positive, blood creatinine increased, blood alkaline phosphatase increased, blood urea increased, activated partial</p><p style="margin-left:1.45pt">thromboplastin time prolonged</p></td><td style="height:174.95pt; vertical-align:top; width:125px"><p style="margin-left:1.45pt; margin-right:2.25pt">blood glucose decreased, blood bilirubin increased, prothrombin time prolonged</p></td><td style="height:174.95pt; vertical-align:top; width:117px"><p style="margin-left:0in">&nbsp;</p></td><td style="height:174.95pt; vertical-align:top; width:151px"><p style="margin-left:1.5pt; margin-right:16.7pt">bleeding time prolonged, gamma‐ glutamyltransferase increased</p></td></tr></tbody></table><p style="margin-right:0in">*ADR identified post marketing</p><p>Piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients.</p><p><em>Beta‐lactam&nbsp;antibiotic&nbsp;class&nbsp;effects</em></p><p>Beta‐lactam&nbsp; antibiotics,&nbsp; including&nbsp; piperacillin&nbsp; tazobactam,&nbsp; may&nbsp; lead&nbsp; to&nbsp; manifestations&nbsp; of&nbsp; encephalopathy&nbsp;and&nbsp;convulsions&nbsp;(see&nbsp;section&nbsp;4.4).</p><p><u>Reporting&nbsp;of&nbsp;suspected&nbsp;adverse&nbsp;reactions&nbsp;</u></p><p>Reporting&nbsp; suspected&nbsp; adverse&nbsp; reactions&nbsp; after&nbsp; authorisation&nbsp; of&nbsp; the&nbsp; medicinal&nbsp; product&nbsp; is&nbsp;important.&nbsp;It&nbsp;allows&nbsp;continued&nbsp;monitoring&nbsp;of&nbsp;</p><p>the&nbsp;benefit/risk&nbsp;balance&nbsp;of&nbsp;the&nbsp;medicinal&nbsp;product.&nbsp; Healthcare&nbsp;professionals&nbsp;are&nbsp;asked&nbsp;to&nbsp;report&nbsp;any&nbsp;suspected&nbsp;adverse&nbsp;reactions&nbsp;via:&nbsp;</p><ul><li>Saudi&nbsp;Arabia&nbsp;</li></ul><p>The&nbsp;National&nbsp;Pharmacovigilance&nbsp;Centre&nbsp;(NPC)&nbsp;&nbsp;</p><p>SFDA&nbsp;Call&nbsp;Center:&nbsp;19999&nbsp;</p><p>E‐mail:<u>&nbsp;npc.drug@sfda.gov.sa</u></p><p>Website:&nbsp;<u>https://ade.sfda.gov.sa </u></p><ul><li>Other&nbsp;GCC&nbsp;States&nbsp; Please&nbsp;contact&nbsp;the&nbsp;relevant&nbsp;competent&nbsp;authority.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms&nbsp;&nbsp;</u></p><p>There&nbsp;have&nbsp;been&nbsp;post‐marketing&nbsp;reports&nbsp;of&nbsp;overdose&nbsp;with&nbsp;piperacillin/tazobactam.&nbsp;The&nbsp;majority&nbsp;of&nbsp; those&nbsp; events&nbsp; experienced,&nbsp; including&nbsp; nausea,&nbsp; vomiting,&nbsp; and&nbsp; diarrhoea,&nbsp; have&nbsp; also&nbsp; been&nbsp; reported&nbsp; with&nbsp; the&nbsp; usual&nbsp; recommended&nbsp; dose.&nbsp; Patients&nbsp; may&nbsp; experience&nbsp; neuromuscular&nbsp; excitability&nbsp; or&nbsp; convulsions&nbsp; if&nbsp; higher&nbsp; than&nbsp; recommended&nbsp; doses&nbsp; are&nbsp; given&nbsp; intravenously&nbsp; (particularly&nbsp; in&nbsp; the&nbsp; presence&nbsp;of&nbsp;renal&nbsp;failure).&nbsp;</p><p><u>Treatment</u>&nbsp;&nbsp;</p><p>In&nbsp;the&nbsp;event&nbsp;of&nbsp;an&nbsp;overdose,&nbsp;piperacillin/tazobactam&nbsp;treatment&nbsp;should&nbsp;be&nbsp;discontinued.&nbsp;No&nbsp;specific&nbsp; antidote&nbsp;is&nbsp;known.&nbsp; Treatment&nbsp;should&nbsp;be&nbsp;supportive&nbsp;and&nbsp;symptomatic&nbsp;according&nbsp;to&nbsp;the&nbsp;patient&#39;s&nbsp;clinical&nbsp;presentation.&nbsp;</p><p>Excessive&nbsp; serum&nbsp; concentrations&nbsp; of&nbsp; either&nbsp; piperacillin&nbsp; or&nbsp; tazobactam&nbsp; may&nbsp; be&nbsp; reduced&nbsp; by&nbsp; haemodialysis&nbsp;(see&nbsp;section&nbsp;4.4).&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic&nbsp;group:&nbsp;Antibacterials&nbsp;for&nbsp;systemic&nbsp;use,&nbsp;Combinations&nbsp;of&nbsp;penicillins&nbsp;incl.&nbsp;beta‐ lactamase&nbsp;inhibitors;&nbsp;ATC&nbsp;code:&nbsp;J01C&nbsp;R05</p><p><u>Mechanism&nbsp;of&nbsp;action&nbsp;</u>&nbsp;</p><p>Piperacillin,&nbsp;a&nbsp;broad‐spectrum,&nbsp;semisynthetic&nbsp;penicillin&nbsp;exerts&nbsp;bactericidal&nbsp;activity&nbsp;by&nbsp;inhibition&nbsp;of&nbsp; both&nbsp;septum&nbsp;and&nbsp;cell‐wall&nbsp;synthesis.&nbsp;</p><p>Tazobactam,&nbsp; a&nbsp; beta‐lactam&nbsp; structurally&nbsp; related&nbsp; to&nbsp; penicillins,&nbsp; is&nbsp; an&nbsp; inhibitor&nbsp; of&nbsp; many&nbsp; beta‐ lactamases,&nbsp; which&nbsp; commonly&nbsp; cause&nbsp; resistance&nbsp; to&nbsp; penicillins&nbsp; and&nbsp; cephalosporins&nbsp; but&nbsp; it&nbsp; does&nbsp; not&nbsp; inhibit&nbsp;AmpC&nbsp;enzymes&nbsp;or&nbsp;metallo&nbsp;beta‐lactamases.&nbsp;Tazobactam&nbsp;extends&nbsp;the&nbsp;antibiotic&nbsp;spectrum&nbsp;of&nbsp; piperacillin&nbsp; to&nbsp; include&nbsp; many&nbsp; beta‐lactamase‐producing&nbsp; bacteria&nbsp;that&nbsp; have&nbsp; acquired&nbsp; resistance&nbsp; to&nbsp; piperacillin&nbsp;alone.&nbsp;</p><p><u>Pharmacokinetic/Pharmacodynamic&nbsp;relationship</u>&nbsp;&nbsp;</p><p>The&nbsp; time&nbsp; above&nbsp; the&nbsp; minimum&nbsp; inhibitory&nbsp; concentration&nbsp; (T&gt;MIC)&nbsp; is&nbsp; considered&nbsp; to&nbsp; be&nbsp; the&nbsp; major&nbsp;pharmacodynamic&nbsp;determinant&nbsp;of</p><p>&nbsp;efficacy&nbsp;for&nbsp;piperacillin.&nbsp;</p><p><u>Mechanism&nbsp;of&nbsp;resistance&nbsp;</u>&nbsp;</p><p>The&nbsp;two&nbsp;main&nbsp;mechanisms&nbsp;of&nbsp;resistance&nbsp;to&nbsp;piperacillin/tazobactam&nbsp;are:&nbsp;</p><ul><li>Inactivation&nbsp; of&nbsp; the&nbsp; piperacillin&nbsp; component&nbsp; by&nbsp; those&nbsp; beta‐lactamases&nbsp; that&nbsp; are&nbsp; not&nbsp; inhibited&nbsp; by&nbsp; tazobactam:&nbsp;beta‐lactamases&nbsp;in&nbsp;the&nbsp;Molecular&nbsp;class&nbsp;B,&nbsp;C&nbsp;and&nbsp;D.&nbsp;In&nbsp;addition,&nbsp;tazobactam&nbsp;does&nbsp;not&nbsp; provide&nbsp;protection&nbsp;against&nbsp;extended‐spectrum&nbsp;beta‐lactamases&nbsp;(ESBLs)&nbsp;in&nbsp;the&nbsp;Molecular&nbsp;class&nbsp;A&nbsp; and&nbsp;D&nbsp;enzyme&nbsp;groups.&nbsp;</li><li>&nbsp; Alteration&nbsp;of&nbsp;penicillin‐binding&nbsp;proteins&nbsp; (PBPs),&nbsp;which&nbsp; results&nbsp;in&nbsp; the&nbsp; reduction&nbsp;of&nbsp; the&nbsp;affinity&nbsp;of&nbsp; piperacillin&nbsp;for&nbsp;the&nbsp;molecular&nbsp;target&nbsp;in&nbsp;bacteria.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Additionally,&nbsp;alterations&nbsp; in&nbsp; bacterial&nbsp;membrane&nbsp; permeability,&nbsp;as&nbsp;well&nbsp;as&nbsp;expression&nbsp; of&nbsp;multi‐drug&nbsp;efflux&nbsp;pumps,&nbsp;may&nbsp;cause&nbsp;or&nbsp;contribute &nbsp;to&nbsp;bacterial&nbsp;resistance&nbsp;to&nbsp;piperacillin/tazobactam,&nbsp;especially&nbsp; in&nbsp;Gram‐negative&nbsp;bacteria.&nbsp;</li></ul><p><u>Breakpoints</u>&nbsp;&nbsp;</p><table cellspacing="0" cellpadding="0" border="1" style="width:601px"><tbody><tr><td colspan="2" style="border-color:#7a7a7a; height:47.95pt; vertical-align:top; width:598px"><p style="margin-left:1.4pt; margin-right:.6pt; text-align:justify"><strong>EUCAST Clinical MIC Breakpoints for piperacillin/tazobactam (EUCAST Clinical Breakpoint </strong><strong>Table Version 10.0, valid from 2020‐01‐01). For Susceptibility Testing Purposes, the Concentration of Tazobactam is Fixed at 4 mg/l</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:187px"><p><strong>Pathogen</strong></p></td><td style="height:17.9pt; vertical-align:top; width:407px"><p style="margin-left:1.35pt; margin-right:0in"><strong>Species‐related breakpoints (S&le;/R&gt;), mg/L of piperacillin</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:32.9pt; vertical-align:top; width:187px"><p><em>Enterobacterales</em></p><p>(formerly&nbsp;<em>Enterobacteriaceae</em>)</p></td><td style="height:32.9pt; vertical-align:top; width:407px"><p style="margin-left:1.35pt; margin-right:0in">8/16</p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:187px"><p><em>Pseudomonas aeruginosa</em></p></td><td style="height:17.9pt; vertical-align:top; width:407px"><p style="margin-left:1.35pt; margin-right:0in">&lt;0.001/16<sup>1</sup></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:187px"><p><em>Staphylococcus </em>species</p></td><td style="height:17.9pt; vertical-align:top; width:407px"><p style="margin-left:1.35pt; margin-right:0in"><sup>_2</sup></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:187px"><p><em>Enterococcus </em>species</p></td><td style="height:17.9pt; vertical-align:top; width:407px"><p style="margin-left:1.35pt; margin-right:0in"><sup>_3</sup></p></td></tr><tr><td style="border-color:#7a7a7a; height:32.9pt; vertical-align:top; width:187px"><p style="margin-left:1.4pt; margin-right:11.15pt"><em>Streptococcus </em>Groups A, B, C, and G</p></td><td style="height:32.9pt; vertical-align:top; width:407px"><p style="margin-left:1.35pt; margin-right:0in"><sup>_4</sup></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:187px"><p><em>Streptococcus pneumoniae</em></p></td><td style="height:17.9pt; vertical-align:top; width:407px"><p style="margin-left:1.35pt; margin-right:0in"><sup>_5</sup></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:187px"><p>Viridans group streptococci</p></td><td style="height:17.9pt; vertical-align:top; width:407px"><p style="margin-left:1.35pt; margin-right:0in"><sup>_6</sup></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:187px"><p><em>Haemophilus influenzae</em></p></td><td style="height:17.9pt; vertical-align:top; width:407px"><p style="margin-left:1.35pt; margin-right:0in">0.25/0.25</p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:187px"><p><em>Moraxella catarrhalis</em></p></td><td style="height:17.9pt; vertical-align:top; width:407px"><p style="margin-left:1.35pt; margin-right:0in">_<sup>7</sup></p></td></tr><tr><td style="border-color:#7a7a7a; height:32.9pt; vertical-align:top; width:187px"><p>Gram‐positive anaerobes</p><p>(except <em>Clostridioides difficile</em>)</p></td><td style="height:32.9pt; vertical-align:top; width:407px"><p style="margin-left:1.35pt; margin-right:0in">8/16</p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:187px"><p>Gram‐negative anaerobes</p></td><td style="height:17.9pt; vertical-align:top; width:407px"><p style="margin-left:1.35pt; margin-right:0in">8/16</p></td></tr><tr><td style="border-color:#7a7a7a; height:32.9pt; vertical-align:top; width:187px"><p>Non‐species related (PK/PD)</p><p>breakpoints</p></td><td style="height:32.9pt; vertical-align:top; width:407px"><p style="margin-left:1.35pt; margin-right:0in">4/16</p></td></tr><tr><td colspan="2" style="border-color:#7a7a7a; height:334.7pt; vertical-align:top; width:598px"><p style="margin-left:1.4pt; margin-right:.65pt; text-align:justify"><sup>1</sup> For several agents, EUCAST has introduced breakpoints which categorise wild‐type organisms (organisms without phenotypically detectable acquired resistance mechanisms to the agent) as &quot;Susceptible, increased exposure (I)&quot; instead of &quot;Susceptible, standard dosing regimen (S)&quot;. Susceptible breakpoints for these organism‐agent combinations are listed as arbitrary, &quot;off scale&quot; breakpoints of S &le; 0.001 mg/L.</p><p style="margin-left:1.4pt; margin-right:.6pt; text-align:justify"><sup>2</sup> Most staphylococci are penicillinase producers, and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to &beta;‐lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. Ampicillin susceptible <em>S. saprophyticus </em>are <em>mecA</em>‐negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta‐lactamase inhibitor).</p><p style="margin-right:.65pt; text-align:justify"><sup>3</sup> Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta‐lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in <em>E. faecalis </em>(confirm with MIC) but common in <em>E. faecium</em>.</p><p style="margin-right:.7pt; text-align:justify"><sup>4</sup> The susceptibility of <em>Streptococcus </em>groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for <em>Streptococcus </em>group B. <em>Streptococcus </em>groups A, B, C and G do not produce beta‐lactamase. The addition of a beta‐lactamase inhibitor does not add clinical benefit.</p><p style="margin-right:.7pt; text-align:justify"><sup>5</sup> The oxacillin 1 &micro;g disk screen test or a benzylpenicillin MIC test shall be used to exclude beta‐lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone &ge;20 mm, or benzylpenicillin MIC &le;0.06 mg/L) all beta‐lactam agents for which clinical breakpoints are available, including those with &ldquo;Note&rdquo; can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as &ldquo;susceptible, increased exposure&rdquo; (I). <em>Streptococcus pneumoniae </em>do not produce beta‐lactamase. The addition of a beta‐lactamase inhibitor does not add clinical benefit. Susceptibility inferred from ampicillin (MIC or zone diameter).</p><p style="margin-left:1.4pt; margin-right:.75pt; text-align:justify"><sup>6</sup> For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.</p><p style="text-align:justify"><sup>7</sup> Susceptibility can be inferred from amoxicillin‐clavulanic acid.</p><p style="text-align:justify">&nbsp;</p></td></tr></tbody></table><p><u>Susceptibility</u>&nbsp;&nbsp;</p><p>The&nbsp;prevalence&nbsp;of&nbsp;acquired&nbsp;resistance&nbsp;may&nbsp;vary&nbsp;geographically&nbsp;and&nbsp;with&nbsp;time&nbsp;for&nbsp;selected&nbsp;species,&nbsp; and&nbsp; local&nbsp; information&nbsp; on&nbsp; resistance&nbsp; is&nbsp; desirable,&nbsp; particularly&nbsp;when&nbsp; treating&nbsp; severe&nbsp; infections.&nbsp; As&nbsp; necessary,&nbsp;expert&nbsp;advice&nbsp;should&nbsp;be&nbsp;sought&nbsp;when&nbsp;the&nbsp;local&nbsp;prevalence&nbsp;of&nbsp;resistance&nbsp;is&nbsp;such&nbsp;that&nbsp;the&nbsp; utility&nbsp;of&nbsp;the&nbsp;agent&nbsp;in&nbsp;at&nbsp;least&nbsp;some&nbsp;types&nbsp;of&nbsp;infections&nbsp;is&nbsp;questionable.</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><strong>Groupings of relevant species according to piperacillin/tazobactam susceptibility</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><u>Aerobic Gram‐positive micro‐organisms</u></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Enterococcus faecalis </em>(ampicillin‐ or penicillin‐susceptible isolates only)</p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Listeria monocytogenes</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Staphylococcus aureus </em>(methicillin‐susceptible isolates only)</p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Staphylococcus </em>species<em>, coagulase negative </em>(methicillin‐susceptible isolates only)</p></td></tr><tr><td style="border-color:#7a7a7a; height:32.9pt; vertical-align:top; width:423.05pt"><p><em>Streptococcus agalactiae </em>(Group B streptococci)<sup>&dagger;</sup></p><p><em>Streptococcus pyogenes </em>(Group A streptococci)<sup>&dagger;</sup></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><u>Aerobic Gram‐negative micro‐organisms</u></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Citrobacter koseri</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.8pt; vertical-align:top; width:423.05pt"><p><em>Haemophilus influenzae</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Moraxella catarrhalis</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Proteus mirabilis</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><u>Anaerobic Gram‐positive micro‐organisms</u></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Clostridium </em>species</p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Eubacterium </em>species</p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p>Anaerobic gram‐positive cocci<sup>&dagger;&dagger;</sup></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.85pt; vertical-align:top; width:423.05pt"><p><u>Anaerobic Gram‐negative micro‐organisms</u></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Bacteroides fragilis </em>group</p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Fusobacterium </em>species</p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Porphyromonas </em>species</p></td></tr><tr><td style="height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Prevotella </em>species</p></td></tr></tbody></table><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#7a7a7a; height:17.85pt; vertical-align:top; width:423.05pt"><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><u>Aerobic Gram‐positive micro‐organisms</u></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Enterococcus faecium</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Streptococcus pneumoniae</em><sup>&dagger;</sup></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Streptococcus viridans group<sup>&dagger;</sup></em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><u>Aerobic Gram‐negative micro‐organisms</u></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Acinetobacter baumannii</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.85pt; vertical-align:top; width:423.05pt"><p><em>Citrobacter freundii</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Enterobacter </em>species</p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Escherichia coli</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Klebsiella pneumoniae</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Morganella morganii</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Proteus vulgaris</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Providencia ssp.</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Pseudomonas aeruginosa</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Serratia </em>species</p></td></tr><tr><td style="border-color:#7a7a7a; height:17.8pt; vertical-align:top; width:423.05pt"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><u>Aerobic Gram‐positive micro‐organisms</u></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Corynebacterium jeikeium</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><u>Aerobic Gram‐negative micro‐organisms</u></p></td></tr><tr><td style="border-color:#7a7a7a; height:47.95pt; vertical-align:top; width:423.05pt"><p style="margin-left:1.4pt; margin-right:314.35pt"><em>Burkholderia cepacia Legionella </em>species <em>Ochrobactrum anthropi</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Stenotrophomonas maltophilia</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.85pt; vertical-align:top; width:423.05pt"><p><u>Other micro‐organisms</u></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Chlamydophila pneumoniae</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:423.05pt"><p><em>Mycoplasma pneumoniae</em></p></td></tr><tr><td style="border-color:#7a7a7a; height:52.05pt; vertical-align:top; width:423.05pt"><p style="margin-left:1.4pt; margin-right:.7pt; text-align:justify">&dagger; Streptococci are not &beta;‐lactamase producing bacteria; resistance in these organisms is due to alterations in penicillin‐ binding proteins (PBPs) and, therefore, susceptible isolates are susceptible to piperacillin alone. Penicillin resistance has not been reported in <em>S. pyogenes</em>.</p><p style="text-align:justify">&dagger;&dagger; Including <em>Anaerococcus</em>, <em>Finegoldia</em>, <em>Parvimonas</em>, <em>Peptoniphilus</em>, and <em>Peptostreptococcus </em>spp.</p></td></tr></tbody></table><p><strong>Merino&nbsp;Trial&nbsp;(blood&nbsp;stream&nbsp;infections&nbsp;due&nbsp;to&nbsp;ESBL&nbsp;producers)</strong></p><p>In&nbsp; a&nbsp; prospective,&nbsp; non‐inferiority,&nbsp; parallel‐group,&nbsp; published&nbsp; randomized&nbsp; clinical&nbsp; trial,&nbsp; definitive&nbsp; (i.e.&nbsp; based&nbsp; on&nbsp; susceptibility&nbsp; confirmed&nbsp; in‐vitro)&nbsp; treatment&nbsp; with&nbsp; piperacillin/tazobactam,&nbsp; compared&nbsp;with&nbsp;meropenem,&nbsp;did&nbsp; not&nbsp; result&nbsp;in&nbsp;a&nbsp; non‐inferior&nbsp;30‐day&nbsp;mortality&nbsp;in&nbsp;adult&nbsp; patients&nbsp; with&nbsp;ceftriaxone‐non‐susceptible&nbsp;E.&nbsp;coli&nbsp;or&nbsp;K.&nbsp;pneumoniae&nbsp;blood&nbsp;stream&nbsp;infections.&nbsp;</p><p>A&nbsp; total&nbsp; of&nbsp; 23&nbsp; of&nbsp; 187&nbsp; patients&nbsp; (12.3%)&nbsp; randomized&nbsp; to&nbsp; piperacillin/tazobactam&nbsp; met&nbsp; the&nbsp; primary&nbsp;outcome&nbsp;of&nbsp;mortality&nbsp;at&nbsp;30&nbsp;days &nbsp;compared&nbsp;with&nbsp;7&nbsp;of&nbsp;191&nbsp;(3.7%)&nbsp;randomized&nbsp;to&nbsp;meropenem&nbsp;(risk&nbsp; difference,&nbsp;8.6%&nbsp;[1‐sided&nbsp;97.5%&nbsp;CI&nbsp;&minus;&nbsp;&infin;&nbsp;to&nbsp;14.5%];&nbsp;P&nbsp;=&nbsp;0.90&nbsp;for&nbsp;non‐inferiority).&nbsp;The&nbsp;difference&nbsp;did&nbsp; not&nbsp;meet&nbsp;the&nbsp;non‐inferiority&nbsp;margin&nbsp;of&nbsp;5%.&nbsp;</p><p>Effects&nbsp;were&nbsp; consistent&nbsp; in&nbsp; an&nbsp;analysis&nbsp; of&nbsp; the&nbsp; per‐protocol&nbsp; population,&nbsp; with&nbsp; 18&nbsp; of&nbsp; 170&nbsp; patients&nbsp; (10.6%)&nbsp;meeting&nbsp; the&nbsp; primary&nbsp; outcome&nbsp;in&nbsp;a&nbsp; piperacillin/tazobactam&nbsp;group&nbsp; compared&nbsp;with&nbsp; 7&nbsp; of&nbsp; 186&nbsp;(3.8%)&nbsp;in&nbsp;the&nbsp;meropenem&nbsp;group&nbsp;(risk&nbsp;difference,&nbsp;6.8%&nbsp;[one‐sided&nbsp;97.5%&nbsp;CI,&nbsp;‐&nbsp;&infin;&nbsp;to&nbsp;12.8%];&nbsp;P&nbsp; =&nbsp;0.76&nbsp;for&nbsp;non‐inferiority).&nbsp;</p><p>Clinical&nbsp; and&nbsp;microbiological&nbsp; resolution&nbsp; (secondary&nbsp; outcomes)&nbsp; by&nbsp; day&nbsp; 4&nbsp; occurred&nbsp; in&nbsp; 121&nbsp; of&nbsp; 177&nbsp; patients&nbsp; (68.4%)&nbsp; in&nbsp; the&nbsp; piperacillin/tazobactam&nbsp; group&nbsp; compared&nbsp; with&nbsp; 138&nbsp; of&nbsp; 185&nbsp; (74.6%),&nbsp; randomized&nbsp; to&nbsp; meropenem&nbsp; (risk&nbsp; difference,&nbsp; 6.2%&nbsp; [95%&nbsp; CI&nbsp; &minus;&nbsp; 15.5&nbsp; to&nbsp; 3.1%];&nbsp; P&nbsp; =&nbsp; 0.19).&nbsp;For&nbsp; secondary&nbsp;outcomes,&nbsp;statistical&nbsp;tests&nbsp;were&nbsp;2‐sided,&nbsp;with&nbsp;a&nbsp;P&nbsp;&lt;0.05&nbsp;considered&nbsp;significant.</p><p>In&nbsp; this&nbsp; trial,&nbsp; a&nbsp; mortality&nbsp; imbalance&nbsp; between&nbsp; study&nbsp; groups&nbsp; was&nbsp; found.&nbsp; It&nbsp; was&nbsp; supposed&nbsp; that&nbsp; deaths&nbsp; occurred&nbsp; in&nbsp; piperacillin/tazobactam&nbsp; group&nbsp; were&nbsp; related&nbsp; to&nbsp; underlying&nbsp; diseases&nbsp; rather&nbsp; than&nbsp;to&nbsp;the&nbsp;concomitant&nbsp;infection.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption&nbsp;</u>&nbsp;</p><p>The&nbsp;peak&nbsp;piperacillin&nbsp;and&nbsp;tazobactam&nbsp;concentrations&nbsp;after&nbsp;4&nbsp;g/0.5&nbsp;g&nbsp;administered&nbsp;over&nbsp;30&nbsp;minutes&nbsp;by&nbsp;intravenous&nbsp;infusion&nbsp;are&nbsp;298&nbsp;&micro;g/ml&nbsp;and&nbsp;34&nbsp;&micro;g/ml</p><p>respectively.&nbsp;</p><p><u>Distribution</u>&nbsp;&nbsp;</p><p>Both&nbsp; piperacillin&nbsp;and&nbsp; tazobactam&nbsp; are&nbsp;approximately&nbsp; 30%&nbsp; bound&nbsp; to&nbsp; plasma&nbsp; proteins.&nbsp;The&nbsp; protein&nbsp;binding&nbsp;of&nbsp;either&nbsp;piperacillin&nbsp;or&nbsp; tazobactam&nbsp;is&nbsp;unaffected&nbsp;by&nbsp;the&nbsp;presence&nbsp;of&nbsp;the&nbsp;other&nbsp;compound.&nbsp; Protein&nbsp;binding&nbsp;of&nbsp;the&nbsp;tazobactam&nbsp;metabolite&nbsp;is&nbsp;negligible.&nbsp; Piperacillin/tazobactam&nbsp;is&nbsp;widely&nbsp;distributed&nbsp;in&nbsp;tissues&nbsp;and&nbsp;body&nbsp;fluids&nbsp;including&nbsp;intestinal&nbsp;mucosa,&nbsp; gallbladder,&nbsp;lung,&nbsp;bile,&nbsp;and&nbsp;bone. Mean&nbsp;tissue&nbsp;concentrations&nbsp;are&nbsp;generally&nbsp;50&nbsp;to&nbsp;100%&nbsp;of&nbsp;those&nbsp;in plasma.&nbsp;Distribution&nbsp;into&nbsp;cerebrospinal&nbsp;fluid&nbsp;is&nbsp;low&nbsp;in&nbsp;subjects&nbsp;with&nbsp;non‐inflamed&nbsp;meninges,&nbsp;as&nbsp;with&nbsp; other&nbsp;penicillins.&nbsp;&nbsp;</p><p><u>Biotransformation&nbsp;</u>&nbsp;</p><p>Piperacillin&nbsp;is&nbsp;metabolised&nbsp;to&nbsp;a&nbsp;minor&nbsp;microbiologically&nbsp;active&nbsp;desethyl&nbsp;metabolite.&nbsp;Tazobactam&nbsp;is&nbsp;metabolised&nbsp;to&nbsp;a&nbsp;single&nbsp;metabolite&nbsp;that&nbsp;has&nbsp;been</p><p>&nbsp;found&nbsp;to&nbsp;be&nbsp;microbiologically&nbsp;inactive.&nbsp;</p><p><u>Elimination</u>&nbsp;&nbsp;</p><p>Piperacillin&nbsp; and&nbsp; tazobactam&nbsp; are&nbsp; eliminated&nbsp; via&nbsp; the&nbsp; kidney&nbsp; by&nbsp; glomerular&nbsp; filtration&nbsp; and&nbsp; tubular&nbsp; secretion.&nbsp;&nbsp;</p><p>Piperacillin&nbsp; is&nbsp; excreted&nbsp; rapidly&nbsp; as&nbsp; unchanged&nbsp; substance,&nbsp; with&nbsp; 68%&nbsp; of&nbsp; the&nbsp; administered&nbsp;dose&nbsp;appearing&nbsp;in&nbsp;the&nbsp;urine.&nbsp;Tazobactam&nbsp;and&nbsp;its&nbsp; metabolite&nbsp;are&nbsp;eliminated &nbsp;primarily&nbsp;by&nbsp;renal&nbsp;excretion,&nbsp; with&nbsp;80%&nbsp;of&nbsp;the&nbsp;administered&nbsp;dose&nbsp;appearing&nbsp;as&nbsp;unchanged&nbsp;substance&nbsp;and&nbsp; the&nbsp;remainder&nbsp;as&nbsp; the&nbsp; single&nbsp;metabolite.&nbsp;Piperacillin,&nbsp;tazobactam,&nbsp;and&nbsp;desethyl&nbsp;piperacillin&nbsp;are&nbsp;also&nbsp;secreted&nbsp;into&nbsp;the&nbsp;bile.&nbsp; &nbsp;&nbsp; Following&nbsp;single&nbsp;or&nbsp;multiple&nbsp;doses&nbsp;of&nbsp;piperacillin/tazobactam&nbsp;to&nbsp;healthy&nbsp;subjects,&nbsp;the&nbsp;plasma&nbsp;half‐ life&nbsp; of&nbsp; piperacillin&nbsp;and&nbsp; tazobactam&nbsp; ranged&nbsp; from&nbsp; 0.7&nbsp; to&nbsp; 1.2&nbsp; hours&nbsp; and&nbsp;was&nbsp; unaffected&nbsp; by&nbsp; dose&nbsp; or&nbsp; duration&nbsp;of&nbsp;infusion.&nbsp;The&nbsp;elimination&nbsp;half‐lives&nbsp;of&nbsp;both&nbsp;piperacillin&nbsp;and&nbsp; tazobactam&nbsp;are&nbsp;increased&nbsp; with&nbsp;decreasing&nbsp;renal&nbsp;clearance.&nbsp;&nbsp;</p><p>There&nbsp;are&nbsp; no&nbsp; significant&nbsp; changes&nbsp; in&nbsp; piperacillin&nbsp; pharmacokinetics&nbsp; due&nbsp; to&nbsp; tazobactam.&nbsp; Piperacillin&nbsp;appears&nbsp;to&nbsp;slightly&nbsp;reduce&nbsp; the&nbsp;clearance&nbsp;of&nbsp;tazobactam.&nbsp;&nbsp;</p><p><u>Special&nbsp;populations</u>&nbsp;</p><p>The&nbsp; half‐life&nbsp; of&nbsp; piperacillin&nbsp; and&nbsp; of&nbsp; tazobactam&nbsp; increases&nbsp; by&nbsp; approximately&nbsp; 25%&nbsp; and&nbsp; 18%,&nbsp;respectively,&nbsp;in&nbsp;patients&nbsp;with&nbsp;hepatic&nbsp; cirrhosis&nbsp;compared&nbsp;to&nbsp;healthy&nbsp;subjects.&nbsp;</p><p>The&nbsp; half‐life&nbsp; of&nbsp; piperacillin&nbsp; and&nbsp; tazobactam&nbsp; increases&nbsp; with&nbsp; decreasing&nbsp; creatinine&nbsp; clearance.&nbsp; The&nbsp; increase&nbsp; in&nbsp; half‐life&nbsp; is&nbsp; two‐fold&nbsp; and&nbsp; four‐fold&nbsp; for&nbsp; piperacillin&nbsp; and&nbsp; tazobactam,&nbsp; respectively,&nbsp; at&nbsp; creatinine&nbsp;clearance&nbsp;below&nbsp;20&nbsp;ml/min&nbsp;compared&nbsp;to&nbsp;patients&nbsp;with&nbsp;normal&nbsp;renal&nbsp;function.&nbsp;</p><p>Haemodialysis&nbsp; removes&nbsp; 30%&nbsp; to&nbsp; 50%&nbsp; of&nbsp; piperacillin/tazobactam,&nbsp; with&nbsp; an&nbsp; additional&nbsp; 5%&nbsp; of&nbsp; the&nbsp; tazobactam&nbsp; dose&nbsp; removed&nbsp; as&nbsp; the&nbsp; tazobactam&nbsp; metabolite.&nbsp; Peritoneal&nbsp; dialysis&nbsp; removes&nbsp; approximately&nbsp;6%&nbsp;and&nbsp;21%&nbsp;of&nbsp;the&nbsp;piperacillin&nbsp;and&nbsp;tazobactam&nbsp;doses,&nbsp;respectively,&nbsp;with&nbsp;up&nbsp;to&nbsp;18%&nbsp; of&nbsp;the&nbsp;tazobactam&nbsp;dose&nbsp;removed&nbsp;as&nbsp;the&nbsp;tazobactam&nbsp;metabolite.&nbsp;</p><p><em>Paediatric&nbsp;population</em>&nbsp;&nbsp;</p><p>In&nbsp; a&nbsp; population&nbsp; PK&nbsp; analysis,&nbsp; estimated&nbsp; clearance&nbsp; for&nbsp; 9‐month‐old&nbsp; to&nbsp; 12&nbsp; year‐old&nbsp; patients&nbsp; was&nbsp;comparable&nbsp;to&nbsp;adults,&nbsp;with&nbsp;a&nbsp;population &nbsp;mean&nbsp;(SE)&nbsp;value&nbsp;of&nbsp;5.64&nbsp;(0.34)&nbsp;ml/min/kg.&nbsp;The&nbsp;piperacillin&nbsp; clearance&nbsp;estimate&nbsp;is&nbsp;80%&nbsp;of&nbsp;this&nbsp;value&nbsp;for&nbsp;paediatric&nbsp;patients&nbsp;2‐9&nbsp;months&nbsp;of&nbsp;age.&nbsp;</p><p>The&nbsp;population&nbsp; mean&nbsp;(SE)&nbsp;for&nbsp;piperacillin&nbsp;volume&nbsp;of&nbsp;distribution&nbsp;is&nbsp;0.243&nbsp;(0.011)&nbsp;l/kg&nbsp;and&nbsp;is&nbsp;independent&nbsp;of&nbsp;age.&nbsp;</p><p><em>Elderly&nbsp;patients&nbsp;</em></p><p>The&nbsp;mean&nbsp;half‐life&nbsp; for&nbsp;piperacillin&nbsp;and&nbsp;tazobactam&nbsp;were&nbsp;32%&nbsp;and&nbsp;55%&nbsp;longer,&nbsp;respectively,&nbsp;in&nbsp;the&nbsp; elderly&nbsp; compared&nbsp; with&nbsp; younger&nbsp; subjects.&nbsp; This&nbsp; difference&nbsp; may&nbsp; be&nbsp; due&nbsp; to&nbsp; age‐related&nbsp; changes&nbsp; in&nbsp; creatinine&nbsp;clearance.&nbsp;</p><p><em>Race&nbsp;</em></p><p>No&nbsp;difference&nbsp;in&nbsp;piperacillin&nbsp;or&nbsp; tazobactam&nbsp; pharmacokinetics&nbsp;was&nbsp; observed&nbsp;between&nbsp;Asian&nbsp; (n=9)&nbsp;and&nbsp;Caucasian&nbsp;(n=9)&nbsp;healthy&nbsp;volunteers</p><p>&nbsp;who&nbsp;received&nbsp;single&nbsp;4&nbsp;g/0.5&nbsp;g&nbsp;doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‐clinical&nbsp;data&nbsp;reveal&nbsp;no&nbsp;special&nbsp;hazard&nbsp; for&nbsp;humans&nbsp;based&nbsp;on&nbsp;conventional&nbsp;studies&nbsp;of&nbsp;repeated&nbsp; dose&nbsp; toxicity&nbsp; and&nbsp; genotoxicity.&nbsp; Carcinogenicity&nbsp; studies&nbsp; have&nbsp; not&nbsp; been&nbsp; conducted&nbsp; with&nbsp; piperacillin/tazobactam.&nbsp;</p><p>A&nbsp; fertility&nbsp; and&nbsp; general&nbsp; reproduction&nbsp; study&nbsp; in&nbsp; rats&nbsp; using&nbsp; intraperitoneal&nbsp; administration&nbsp; of&nbsp; tazobactam&nbsp; or&nbsp; the&nbsp;combination&nbsp; piperacillin/tazobactam&nbsp; reported&nbsp;a&nbsp; decrease&nbsp;in&nbsp;litter&nbsp; size&nbsp;and&nbsp;an&nbsp; increase&nbsp; in&nbsp; fetuses&nbsp; with&nbsp; ossification&nbsp; delays&nbsp; and&nbsp; variations&nbsp; of&nbsp; ribs,&nbsp; concurrent&nbsp; with&nbsp; maternal&nbsp; toxicity.&nbsp; Fertility&nbsp; of&nbsp; the&nbsp; F1&nbsp; generation&nbsp; and&nbsp; embryonic&nbsp; development&nbsp; of&nbsp; F2&nbsp; generation&nbsp; were&nbsp; not&nbsp; impaired.&nbsp;</p><p>Teratogenicity&nbsp; studies&nbsp; using&nbsp; intravenous&nbsp; administration&nbsp; of&nbsp; tazobactam&nbsp; or&nbsp; the&nbsp; combination&nbsp; piperacillin/tazobactam&nbsp; in&nbsp; mice&nbsp; and&nbsp; rats&nbsp; resulted&nbsp; in&nbsp; slight&nbsp; reductions&nbsp; in&nbsp; rat&nbsp; fetal&nbsp; weights&nbsp; at&nbsp; maternally&nbsp;toxic&nbsp;doses&nbsp;but&nbsp;did&nbsp;not&nbsp;show&nbsp;teratogenic&nbsp;effects.&nbsp;</p><p>Peri/postnatal&nbsp;development&nbsp;was&nbsp;impaired&nbsp;(reduced&nbsp;pup&nbsp;weights,&nbsp;increase&nbsp;in&nbsp;stillbirths,&nbsp;increase&nbsp;in&nbsp; pup&nbsp; mortality)&nbsp; concurrent&nbsp; with&nbsp; maternal&nbsp; toxicity&nbsp; after&nbsp; intraperitoneal&nbsp; administration&nbsp; of&nbsp; tazobactam&nbsp;or&nbsp;the&nbsp;combination&nbsp;piperacillin/tazobactam&nbsp;in&nbsp;the&nbsp;rat.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This&nbsp; medicinal&nbsp; product&nbsp; must&nbsp; not&nbsp; be&nbsp; mixed&nbsp; with&nbsp; other&nbsp; medicinal&nbsp; products&nbsp; except&nbsp; those&nbsp; mentioned&nbsp;in&nbsp;section&nbsp;6.6.&nbsp;&nbsp;</p><p>Whenever&nbsp; piperacillin/tazobactam&nbsp; is&nbsp; used&nbsp; concurrently&nbsp; with&nbsp; another&nbsp; antibiotic&nbsp; (e.g.&nbsp; aminoglycosides),&nbsp; the&nbsp; substances&nbsp;must&nbsp;be&nbsp;administered&nbsp; separately.&nbsp;The&nbsp;mixing&nbsp;of&nbsp;beta‐lactam&nbsp; antibiotics&nbsp; with&nbsp; an&nbsp; aminoglycoside&nbsp; in&nbsp; vitro&nbsp; can&nbsp; result&nbsp; in&nbsp; substantial&nbsp; inactivation&nbsp; of&nbsp; the&nbsp; aminoglycoside.&nbsp;</p><p>Piperacillin/tazobactam&nbsp; should&nbsp; not&nbsp; be&nbsp; mixed&nbsp; with&nbsp; other&nbsp; substances&nbsp; in&nbsp; a&nbsp; syringe&nbsp; or&nbsp; infusion&nbsp; bottle&nbsp;since&nbsp;compatibility&nbsp;has&nbsp;not&nbsp;been&nbsp;established.</p><p>Due&nbsp; to&nbsp;chemical&nbsp;instability,&nbsp;piperacillin/tazobactam&nbsp; should&nbsp;not&nbsp;be&nbsp;used&nbsp;in&nbsp; solutions&nbsp;containing&nbsp; only&nbsp;sodium&nbsp;bicarbonate.&nbsp;&nbsp; Piperacillin/tazobactam&nbsp;should&nbsp;not&nbsp;be&nbsp;added&nbsp;to&nbsp;blood&nbsp;products&nbsp;or&nbsp;albumin&nbsp;hydrolysates.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial: 24 months. 
Reconstituted solution in vial 
Chemical and physical in‐use stability has been demonstrated for 24 hours when stored at room temperature  and  for  48  hours  when  stored  at  refrigerated  temperature  (2‐8ᵒC),  when reconstituted with one of the compatible solvents for reconstitution (see section 6.6). 

Diluted reconstituted solution, for infusion  
The diluted reconstituted solution when using one of the compatible solvents at the suggested dilution  volume  (see  section  6.6),  demonstrated  chemical  and  physical  in‐use  stability  for  24 hours  when  stored  at  room  temperature  and  for  48  hours  when  stored  at  refrigerated temperature (2‐8ᵒC).
From  a  microbiological  point  of  view,  the  reconstituted  and  diluted  solutions  should  be  used immediately. If not used immediately, in‐use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours when stored at room temperature and 48 hours when stored at refrigerated temperature (2‐8ᵒC).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unopened&nbsp;vial:&nbsp;Do&nbsp;not&nbsp;store&nbsp;above&nbsp;30&deg;C.&nbsp;&nbsp;</p><p>For&nbsp;storage&nbsp;conditions&nbsp;of&nbsp;the&nbsp;reconstituted&nbsp;and&nbsp;diluted&nbsp;medicinal&nbsp;product,&nbsp;see&nbsp;section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>50&nbsp;ml&nbsp;type&nbsp;II&nbsp;glass&nbsp;transparent&nbsp;vials&nbsp;with&nbsp;a&nbsp;bromobutyl&nbsp;stoppers&nbsp;and&nbsp;aluminum&nbsp;flip‐off&nbsp;caps.&nbsp;</p><p>Pack&nbsp;size:&nbsp;1&nbsp;Vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The&nbsp; reconstitution&nbsp;and&nbsp;dilution&nbsp;are&nbsp;to&nbsp;be&nbsp;made&nbsp;under&nbsp;aseptic&nbsp;conditions.&nbsp;The&nbsp;solution&nbsp;is&nbsp; to&nbsp;be&nbsp;inspected&nbsp;visually&nbsp;for&nbsp;particulate&nbsp;matter &nbsp;and&nbsp;discolouration&nbsp;prior&nbsp;to&nbsp;administration.&nbsp;The&nbsp;solution&nbsp; should&nbsp;only&nbsp;be&nbsp;used&nbsp;if&nbsp;the&nbsp;solution&nbsp;is&nbsp;clear&nbsp;and&nbsp;free&nbsp;from&nbsp;particles.&nbsp;</p><p><strong>Intravenous&nbsp;use</strong>&nbsp;</p><p>Reconstitute&nbsp;each&nbsp;vial&nbsp;with&nbsp; the&nbsp;volume&nbsp; of&nbsp; solvent&nbsp; shown&nbsp;in&nbsp; the&nbsp;table&nbsp; below,&nbsp; using&nbsp;one&nbsp; of&nbsp; the&nbsp; compatible&nbsp; solvents&nbsp; for&nbsp; reconstitution.&nbsp; Swirl&nbsp; until&nbsp; dissolved.&nbsp; When&nbsp; swirled&nbsp; constantly,&nbsp; reconstitution&nbsp; generally&nbsp; occurs&nbsp; within&nbsp; 5&nbsp; to&nbsp; 10&nbsp; minutes&nbsp; (for&nbsp; details&nbsp; on&nbsp; handling,&nbsp; please&nbsp; see&nbsp; below).</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:219.55pt"><p><strong>Content of vial</strong></p></td><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:174.9pt"><p><strong>Volume of solvent* to be added to vial</strong></p></td></tr><tr><td style="border-color:#7a7a7a; height:17.9pt; vertical-align:top; width:219.55pt"><p>2 g/0.25 g (2 g piperacillin and 0.25 g tazobactam)</p></td><td style="height:17.9pt; vertical-align:top; width:174.9pt"><p style="margin-left:1.45pt; margin-right:0in">10 ml</p></td></tr><tr><td style="border-color:#7a7a7a; height:.25in; vertical-align:top; width:219.55pt"><p>4 g/0.5 g (4 g piperacillin and 0.5 g tazobactam)</p></td><td style="height:.25in; vertical-align:top; width:174.9pt"><p style="margin-left:1.35pt; margin-right:0in">20 ml</p></td></tr></tbody></table><p style="margin-right:0in"><u>* Compatible solvents for reconstitution:</u><!--[if !supportLists]--></p><p style="margin-right:0in">- 0.9% (9 mg/ml) sodium chloride solution for injection<!--[if !supportLists]--><!--[endif]--></p><p style="margin-right:0in">- Water for injection <sup>(1)</sup><!--[if !supportLists]--><!--[endif]--></p><p style="margin-right:0in">- 5% Glucose</p><p style="margin-right:0in"><sup>(1)</sup> Maximum recommended volume of water for injection per dose is 50 ml.</p><p style="margin-right:16.45pt; text-align:justify">The reconstituted solutions should be withdrawn from the vial by syringe. When reconstituted as directed, the vial contents withdrawn by syringe will provide the labelled amount of piperacillin and tazobactam.</p><p style="margin-right:16.55pt; text-align:justify"><u>The reconstituted solutions may be further diluted to the desired volume (e.g. 50 ml to 150 ml)</u> <u>with one of the following compatible solvents:</u></p><p style="text-align:justify">- 0.9%&nbsp;(9&nbsp;mg/ml)&nbsp;sodium&nbsp;chloride&nbsp;solution&nbsp;for&nbsp;injection</p><p style="text-align:justify">- Water&nbsp;for&nbsp;injection</p><p style="text-align:justify">- 5%&nbsp;Glucose&nbsp;</p><p style="text-align:justify">- 6%&nbsp;Dextrane&nbsp;</p><p style="margin-right:16.55pt; text-align:justify"><strong>Co‐administration&nbsp;with&nbsp;aminoglycosides</strong>&nbsp;&nbsp;</p><p style="margin-right:16.55pt">Due&nbsp; to&nbsp; the&nbsp;<em> in&nbsp; vitro</em>&nbsp; inactivation&nbsp; of&nbsp; the&nbsp; aminoglycoside&nbsp; by&nbsp; beta‐lactam&nbsp; antibiotics,piperacillin/tazobactam&nbsp;and&nbsp;the&nbsp;aminoglycoside &nbsp;are&nbsp;recommended&nbsp;for&nbsp;separate&nbsp;administration.&nbsp; Piperacillin/tazobactam and&nbsp;the&nbsp;aminoglycoside&nbsp;should&nbsp;be&nbsp;reconstituted&nbsp;and&nbsp;diluted&nbsp;separately&nbsp; when&nbsp;concomitant&nbsp;therapy&nbsp;with&nbsp;aminoglycosides&nbsp;is&nbsp;indicated.</p><p style="margin-right:16.55pt">&nbsp; In&nbsp; circumstances&nbsp; where&nbsp; co‐administration&nbsp; is&nbsp; recommended,&nbsp; piperacillin/tazobactam&nbsp; is&nbsp; compatible&nbsp; for&nbsp; simultaneous&nbsp; co‐administration&nbsp; via&nbsp;</p><p style="margin-right:16.55pt">Y‐site&nbsp; infusion&nbsp; only&nbsp; with&nbsp; the&nbsp; following&nbsp; aminoglycosides&nbsp;under&nbsp;the&nbsp;following&nbsp;conditions:</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="height:47.55pt; vertical-align:top; width:74.6pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:1.45pt"><strong>Aminoglycoside</strong></p></td><td style="height:47.55pt; vertical-align:top; width:110.4pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:43.55pt; text-indent:-41.9pt"><strong>Piperacillin/tazobactam </strong><strong>Dose</strong></p></td><td style="height:47.55pt; vertical-align:top; width:110.45pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:.15in; margin-right:.2pt; text-indent:-9.15pt"><strong>Piperacillin/tazobactam </strong><strong>diluent volume (ml)</strong></p></td><td style="height:47.55pt; vertical-align:top; width:74.75pt"><p style="margin-left:1.7pt; margin-right:1.15pt; text-align:center"><strong>Aminoglycoside concentration </strong><strong>range* (mg/ml)</strong></p></td><td style="height:47.55pt; vertical-align:top; width:53.95pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:8.55pt; margin-right:.55pt; text-indent:-6.75pt"><strong>Acceptable </strong><strong>diluents</strong></p></td></tr><tr><td style="height:63.05pt; vertical-align:top; width:74.6pt"><p style="margin-left:1.45pt; margin-right:0in">Amikacin</p></td><td style="height:63.05pt; vertical-align:top; width:110.4pt"><p style="margin-left:32.9pt; margin-right:0in">2 g/0.25 g</p><p style="margin-left:35.65pt; margin-right:0in">4 g/0.5 g</p></td><td style="height:63.05pt; vertical-align:top; width:110.45pt"><p style="margin-left:24.4pt; margin-right:24.05pt; text-align:center">50, 100, 150</p></td><td style="height:63.05pt; vertical-align:top; width:74.75pt"><p style="margin-left:1.5pt; margin-right:1.15pt; text-align:center">1.75 &ndash; 7.5</p></td><td style="height:63.05pt; vertical-align:top; width:53.95pt"><p style="margin-left:.95pt; margin-right:.45pt; text-align:center">0.9%</p><p style="margin-left:.95pt; margin-right:.45pt; text-align:center">sodium</p><p style="margin-left:.95pt; margin-right:.45pt; text-align:center">chloride or</p><p style="margin-left:.95pt; margin-right:.4pt; text-align:center">5% glucose</p></td></tr><tr><td style="height:63.15pt; vertical-align:top; width:74.6pt"><p style="margin-left:1.45pt; margin-right:0in">Gentamicin</p></td><td style="height:63.15pt; vertical-align:top; width:110.4pt"><p style="margin-left:32.9pt; margin-right:0in">2 g/0.25 g</p><p style="margin-left:35.65pt; margin-right:0in">4 g/0.5 g</p></td><td style="height:63.15pt; vertical-align:top; width:110.45pt"><p style="margin-left:24.35pt; margin-right:24.1pt; text-align:center">50, 100, 150</p></td><td style="height:63.15pt; vertical-align:top; width:74.75pt"><p style="margin-left:1.35pt; margin-right:1.15pt; text-align:center">0.7 &ndash; 3.32</p></td><td style="height:63.15pt; vertical-align:top; width:53.95pt"><p style="margin-left:.95pt; margin-right:.45pt; text-align:center">0.9%</p><p style="margin-left:.95pt; margin-right:.45pt; text-align:center">sodium</p><p style="margin-left:.95pt; margin-right:.45pt; text-align:center">chloride or</p><p style="margin-left:.95pt; margin-right:.4pt; text-align:center">5% glucose</p></td></tr></tbody></table><p style="margin-right:16.5pt">* The dose of aminoglycoside should be based on patient weight, status of infection (serious or life‐threatening) and renal function (creatinine clearance).</p><p style="margin-right:16.5pt">Compatibility of piperacillin/tazobactam with other aminoglycosides has not been established. Only the concentration and diluents for amikacin and gentamicin with the dose of piperacillin/tazobactam listed in the above table have been established as compatible for co‐ administration via Y‐site infusion. Simultaneous co‐administration via Y‐site in any manner other than listed above may result in inactivation of the aminoglycoside by piperacillin/tazobactam.</p><p>See section 6.2 for incompatibilities.</p><p style="margin-right:16.55pt">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>For single use only. Discard any unused solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries 
Al‐Kharj Road  
P.O. BOX 106229 
Riyadh 11666, Saudi Arabia 
Tel: + (966‐11) 8107023, + (966‐11) 2142472 
Fax: + (966‐11) 2078170 
e‐mail: SAPV@hikma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                23 May 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>